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ABSTRACT 
Longevity Assurance (LASS) genes also known as Ceramide Synthases (CerS) belong 
to a family of six related genes. CerS gene products have been shown to produce 
ceramide, hence their name CerS. Ceramide is a bio-effector molecule, belonging to the 
family of sphingolipids (SLs), which are important components of cell membranes. 
Ceramide has been implicated in cancer and apoptosis. Cancer still remains the second 
leading cause of death, globally and in South Africa. The proper regulation of the 
balance between cell growth and cell death is essential for cellular homeostasis. Failure 
to properly regulate this balance may lead to pathologic conditions such as cancer 
development. CerSes have been implicated in cancer biology, especially apoptosis, 
through the action of ceramide. The precise roles of CerSes in different cancers is not 
yet fully understood, especially the role of CerS4 and CerS5 in colon and endometrial 
cancers. 
The broad aim of this study was to investigate the role of CerS4 and CerS5 in apoptosis 
and, thus in cancers of the endometrium and colon, which are among the top five 
prevalent cancers globally. Bioinformatics tools (STRING, BioGRID and IntAct 
databases) were used to determine the CerS4 and CerS5 potential protein-interacting 
partners, to assess their possible roles in cancer biology. Sequence alignment tools 
(Multi-Align, Clustal Omega and COBALT) were then used to examine if there was 
sequence similarity between CerS4 and or CerS5 and their possible protein interacting 
partners. Total RNA was extracted from cancerous and non-cancerous cells, or 
calibrator and test samples. Quantitative relative expression of CerS4 and CerS5 was 
then determined in all cell lines, normalised to β-actin. Apoptosis was induced in 
cultured colon cells using 5-fluorouracil, while anastrozole was used to induce 
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apoptosis in endometrial cells. Fluorescence activated cell sorting (FACS) was used to 
analyse and quantify apoptosis. Quantitative Real-Time Polymerase Chain Reaction 
(qRT-PCR) was again used to determine change in expression level of CerS4 and CerS5 
after apoptosis induction. 
Bio-informatics analysis revealed at least 30 proteins that could possibly interact with 
CerS4 and 12 that may interact with CerS5, and these are involved in apoptosis, cell-
cycle regulation, ubiquitination and interestingly in bone and cartilage formation, as 
well as the central nervous system. Surprisingly, no sequence similarity was revealed 
between CerS4 and/or CerS5 and the possible interacting partners, when all aligned 
together. Using quantitative real-time PCR, both LASS4 and 5 were shown to be up-
regulated in colon and endometrial cancer cells. Apoptosis induction resulted in down-
regulation of LASS 4 and LASS 5 in colon and endometrial cancers. These findings 
implicate the involvement of these genes in cancer and apoptosis. Whether these genes 
play a pro- or anti-apoptotic roles in the cancers of the colon and endometrium is not 
conclusive at this stage. It may also be possible that these genes could exert opposing 
roles in the same or different tissues. Targeting this family of genes and understanding 
their precise individual roles in different types of cancer, is a promising therapeutic tool 
to new anti-cancer drug discovery or improving on the existing ones. 
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CHAPTER 1 
INTRODUCTION 
1.1 CANCER 
Cancer is one of the leading causes of mortality globally and may be described as the 
uncontrolled growth of undifferentiated cells in the body (Parkin et al., 2005; Matsumoto et 
al., 2008; Sambo et al., 2012). Normal tissue growth and development require prolific cell 
division, regulated cell differentiation, and appropriately timed cell death or apoptosis 
(Kronja and Orr-Weaver, 2011). Neoaplastic transformation of a tissue that results in tumour 
growth generally occurs when abnormal regulatory mechanisms promote excessive cell 
division, impaired cell differentiation and failure to undergo apoptosis. In most tumour types, 
this aberrant control originates at the genetic level (Parkin et al., 2005). 
The life cycle of a cell consists of two alternating stages, interphase and mitosis, shown in 
figure 1.1. Interphase, which is the longer phase, is further divided into three substages or 
phases and these are: gap 1 (G1), DNA synthesis (S phase) and gap 2 (G2). During G1, cells 
use DNA as a template to transcribe mRNA then to translate mRNA into proteins. DNA is 
replicated in the S phase and this doubles the cellular DNA content. During the G2 phase, the 
DNA repair mechanism corrects any mutations that occurred during the S phase as the cell 
makes final preparations for entry into mitosis. On the other hand, mitosis is a shorter stage 
during which cell division occurs. The end result of mitosis is two identical daughter cells 
each with a complete set of 23 chromosome pairs (Wang et al., 2011). 
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Figure 1.1 – Regulation of the cell cycle:  The cell cycle is an ordered set of events and is divided 
into the Gap 1 (G1) phase, the Synthesis (S)-phase, the G2-phase and the Mitosis (M)-phase. Cells 
multiply and divide in the cell cycle. Cells double their DNA during the S-phase while nuclear and 
cytoplasmic division occurs during the M-phase (Parkin et al., 2005; Kronja and Orr-Weaver, 2011). 
It is hypothesised that failure to properly regulate the cycle, may lead to the survival of 
damaged cells which can lead to the development of pathological conditions such as cancer. 
Tumours may develop as a consequence of genetic alterations that occur at the S-phase. 
These alterations can confer growth advantages to cells as well as the ability to proliferate 
uncontrollably (King and Cidlowski, 1998; Göhler et al., 2005) Compared with normal cells, 
cancer cells lack contact inhibition, that is, they do not stop growing when they touch one 
another and therefore may form tumours that can take over and destroy organs (Matsumoto et 
al., 2008). 
1.2 WHAT CAUSES CANCER? 
Normally, cells have a finite life span, however, sometimes cells acquire genetic changes that 
make them resistant to cell death. Instead of dying cancer cells grow and multiply infinitely, 
aggregating together to form tumours (Vogelstein and Kinzler, 2004; Reddel, 2010). Tumours 
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may be malignant (cancerous) or non-malignant (benign). Malignant tumours have the ability 
to metastasise and invade other parts of the body (Matsumoto, 2008). Typical features of all 
forms of cancer include uncontrolled cell proliferation, resistance to apoptosis, metastasis, 
activation of telomerase, mutation, amplification and re-arrangement of proto-oncogenes and 
deletion or silencing of tumour suppressor genes (MacKenzie et al., 2002; Torkamani et al., 
2009). The transformation process can be simply divided into initiation (genetic alterations), 
clone expansion, apoptotic resistance, and tumour invasion to adjacent cells including 
metastasis to other parts of the body (MacKenzie et al., 2002). The majority of organs in the 
body develop cancer; the endometrium and the colon are also susceptible to cancer. 
Furthermore, there is evidence to suggest that cancers of the colon and endometrium are 
linked to genetic alterations (Wu et al., 2004; Abe et al., 2006). 
1.3 GENES AND THEIR PATHWAYS IN CONTROLLING CANCER 
Cancer is a metabolic disorder with multi-step genetic alterations. Alterations in three types 
of genes are responsible for tumourigenesis and these include: oncogenes, tumour-suppressor 
genes and stability genes (Vogelstein and Kinzler, 2004). Unlike diseases such as cystic 
fibrosis or muscular dystrophy, where mutations in one gene can cause a disease; no single 
gene defect ‘causes’ cancer. Mammalian cells have multiple safeguards to protect themselves 
against potentially lethal effects of cancer gene mutations, and only when several genes are 
defective does an invasive cancer develop (Vogelstein and Kinzler, 2004). In some instances, 
oncogenes are mutated in ways that render the gene constitutively active or active under 
conditions in which the wild-type gene is not. Oncogene activations can result from 
chromosomal translocations, gene amplifications or from subtle intragenic mutations 
affecting crucial residues that regulate the activity of the gene product (Davies et al., 2002). 
Tumour-suppressor genes are targeted in the opposite way by genetic alterations where 
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mutations reduce the activity of the gene product (Santarosa and Ashworth, 2004). Oncogene 
and tumour-suppressor gene mutations all operate similarly at the physiological level: 
meaning that they drive the neoplastic process by increasing tumour cell number through the 
stimulation of cell birth or the inhibition of cell death or cell-cycle arrest. The increase can be 
caused by the activation of genes that drive the cell cycle, by inhibition of normal apoptotic 
processes or facilitation of nutrient supply through enhanced angiogenesis (Vogelstein and 
Kinzler, 2004). A third class of cancer genes, called stability genes or caretakers, promotes 
tumourigenesis in a completely different way when mutated. This class includes the 
mismatch repair (MMR), nucleotide-excision repair (NER) and base-excision repair (BER) 
genes responsible for repairing subtle mistakes made during normal DNA replication or 
induced by exposure to mutagens (Vogelstein and Kinzler, 2004). Other stability genes 
control processes involving large portions of chromosomes, such as those responsible for 
mitotic recombination and chromosomal segregation (for example, BRCA1) (Friedberg, 
2003; Vogelstein and Kinzler, 2004). Stability genes keep genetic alterations to a minimum, 
and thus when they are inactivated, mutations in other genes occur at a higher rate. Most 
genes are potentially affected by the resultant increased rate of mutation, but only mutations 
in oncogenes and tumour-suppressor genes affect net cell growth and can thereby confer a 
selective growth advantage to the mutant cell. As with tumour-suppressor genes, both alleles 
of stability generally must be activated for a physiologal effect to result (Friedberg, 2003). 
Cancer gene mutations enhance net cell growth. For example, several cancer genes directly 
control transitions from a resting stage (G0 or G1) to a replicating phase (S) of the cell cycle. 
The products of these genes include proteins as diverse as cdk4 (a kinase), cyclin D1 (which 
interacts with and activates cdk4), Rb (a transcription factor) and p16 (which interacts with 
and inhibits cdk4) (Sherr, 2000; Classon and Harlow, 2002; Ortega et al., 2002). The genes 
encoding Rb and p16 are tumour-suppressor genes inactivated by mutation, whereas those 
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encoding cdk4 and cyclin D1 are oncogenes activated by mutation. The p53 pathway is 
another example that highlights the importance of pathways inactivation in the development 
and the pathogenesis of cancer, rather than individual genes. The p53 protein is a transcription 
factor that normally inhibits cell growth and stimulates cell death when induced by cellular 
stresses (Vogelstein et al., 2000; Oren, 2003). 
Cancer is a multistep genetic process. It has been proven that mutations in a pathway rather 
than single genes is responsible for tumourigenesis. The p53 and the Rb tumour suppressor 
genes pathways have been implicated in many types of cancer when inactivated, colon 
cancer, for example (Prives and Hall, 1999). Rb has been shown to be a down-stream target 
of ceramide. Activation of Rb by ceramide leads to growth arrest and apoptosis (Ogretmen, 
2006). Ceramide is a sphingolipid which has been implicated in cancer biology (Pwezner-
Jung et al., 2006; Huang et al., 2011). Two pathways result in the synthesis of ceramide and 
these are sphingomyelin (SM) hydrolysis and de novo by Ceramide Synthases (CerSes), also 
known as Longevity Assurance (LASS) genes, which is a family of six related genes 
(Ogretmen, 2006). 
1.4 THE ROLE OF CERAMIDE IN APOPTOSIS 
The cellular levels of endogenous ceramide increase in response to stress causing agents such 
as UV irradiation, hyperthermia (heat stress), or chemotherapeutic agents. The increased 
concentration of ceramide occurs via the activation of de novo synthesis and/or 
sphingomyelinases (SMases) that hydrolyse sphingomyelin (SM) into ceramide. The high 
concentrations of ceramide may mediate anti-proliferative pathways, or inhibit prosurvival 
mechanisms mainly by regulating multiple signaling cascades controlled by protein 
phosphatase 1 and 2A (also known as CAPPs, ceramide-activated protein phosphatases), 
kinases, or cathepsin D. Additionally downstream targets of ceramide signaling include 
 
6 | P a g e  
telomeres, which rapidly shorten, and human telomerase reverse transcriptase (hTERT) 
expression, which is modulated (Ogretmen and Hannun, 2001). Telomerase elongates 
telomeres at the end of chromosomes and is involved in cellular immortalisation and 
malignant transformation when other oncogenic signals are present. Transcription of hTERT, 
which is the catalytic subunit of telomerase, is inhibited by ceramide in a c-Myc dependent 
mechanism (Ogretmen, 2006). Furthermore ceramide also activates retinoblastoma (RB) and 
p53-dependent cell death, and regulates the functions of cyclin-dependent kinases and 
apoptosis related proteins such as Bcl-2, caspases and proteases. Ceramide also induces 
caspase-independent apoptosis (Ogretmen, 2006). In addition, sphingosine-1-phosphate (S1P) 
which is also a bioactive sphingolipid, is considered to be a pro-survival lipid, because of its 
involvement in malignant transformation, cancer proliferation, inflammation, vasculogenesis, 
and resistance to apoptotic cell death (Ogretmen, 2006). Interestingly, in the recent studies by 
Senkal et al., (2010), it has been shown that ceramide acts as a double-edged lipid, either 
inhibiting or promoting apoptosis, depending on the ceramide species produced by various 
CerSes. 
1.5 APOPTOSIS ACTIVATORS 
Apoptosis also known as programmed cell death (PCD) is characterized by a series  of  
distinct  morphological  and  biochemical changes  and plays vital roles in normal cell 
turnover and development in multicellular as well as in unicellular organisms (Sen et al., 
2004).  One of the hallmarks for cancer is resistance to apoptosis (Chaudhry and Asselin, 
2009). DNA topoisomerases are ubiquitous enzymes that catalyse the interconversion of 
topological isomers of DNA molecules and are involved in many vital processes such as 
replication, transcription, recombination, integration and chromosomal segregation (Sen et 
al., 2004).  These enzymes act by sequential breakage and reunion of either one strand (topo 
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I) or both the strands of DNA (topo II) (Sen et al., 2004). DNA topoisomerases have been 
shown to be essential as molecular targets for anti-tumour agents like camptothecin (Wang, 
1991; Sen et al., 2004). 
Camptothecin, a class I DNA topoisomerase inhibitor that stabilizes topo I-DNA covalent 
complex and blocks subsequent rejoining of the DNA break, is widely used as an effective 
anti-tumour drug (Sen et al., 2004).  In cultured cells, Camptothecin inhibits both DNA and 
RNA synthesis, arrests cells in the G2 phase of the cell cycle,  stimulates sister chromatid 
exchanges and chromosomal aberrations, elevates p53 levels, induces multiubiquitination and 
degradation of topo I and activates signal transduction molecules such as proto-oncogenes 
and NF-kb (Sen et al., 2004). Aromatase inhibitors such as anastrozole have been previously 
shown to effectively treat endometrial cancer, while 5-FU has been used to treat colon cancer 
(Ashktorab et al., 2005; Meresman et al., 2005).    
1.5.1 Anastrozole and 5-Fluorouracil (5-FU) 
Aromatase is a key enzyme in the synthesis of estrogen that is responsible for binding of 
testosterone and catalyzes the series of reactions eventually   resulting in estrogen production 
(Jongen et al., 2005).   Previous reports demonstrated that aromatase is present   in endometrial 
cancer tissue, suggesting that aromatase plays a role in converting testosterone into mitogenic 
estrogens in endometrial tissue (Lin et al., 2009). Anastrozole (Sigma-Aldrich, USA), an 
aromatase inhibitor (Burstein et al., 2010) was used to induce apoptosis in endometrial cells 
(Meresman et al., 2005), and is shown in figure 1.2. Five-Fluorouracil is a potent inhibitor of 
thymidylate synthatase (TS), (Lu et al., 2011) which (TS) is the limiting irreversible step in 
the synthesis of DNA. Five-FU (Sigma-Aldrich) has been reported to be active against solid 
tumours like breast, head and neck and cancer of the colon (Wei et al., 2006). It has been 
found that 5-FU induces apoptosis in colon cancer in three ways. Firstly by inhibiting DNA 
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synthesis, secondly by activating the caspase-8 pathway and finally by inducing the 
expression of the Fas-ligand and a p-53-dependent increase in cell surface expression of Fas. 
(Wei et al., 2006). The Fas ligand expression in turn activates transcription factors NF-kB 
and AP-1, which additionally causes tumour cell death via autocrine and paracrine pathways. 
Interestingly, it has been shown that 5-FU dependent apoptosis in colon cancer cells is 
blocked by anti-Fas antibodies. (Ashktorab et al., 2005). The structure of 5-FU, is shown in 
figure 1.3.  
 
Figure 1.2 - Structure of anastrozole:  Anastrozole is an aromatase inhibitor, blocking the synthesis 
of estrogen and thus blocking proliferation. It was used to induce apoptosis in uterine tissue 
(www.drugbank.ca.za). 
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Figure 1.3 - Structure of 5-Fluorouracil (5-FU):  5FU inhibits thymidylate synthatase (TS), which 
is a key enzyme to DNA synthesis in cancer cells. As a result these cancer cells do not pass the S-phase 
and therefore cannot divide and multiply, but undergo apoptosis. (www.drugbank.ca.za). 
1.6 RATIONALE 
Cancer is a multi-step genetic process, being the second leading cause of mortality worldwide 
(Vogelstein and Kinzler, 2004; Moodley et al., 2009). Therefore there is an extensive effort 
to develop new anti-cancer drugs or to improve the existing ones. As a product of CerSes, 
ceramide has been implicated in cancer biology. Much data has been reported on ceramide 
generated by the SM hydrolysis (for example, mutation of SMase in exon 4 in HT-29 colon 
cells). On contrary, little is known about ceramide produced by CerSes, especially in colon 
and endometrial cancers, which are amongst the most prevalent in South Africa (CANSA, 
2012). Furthermore, CerSes have been shown to produce different ceramide molecules 
(Pewzner-Jung et al., 2006). To complicate matters, distinct ceramide molecules produced by 
different CerSes have been shown to exert opposing roles in the same or different tissues, i.e 
CerS1 was shown to play an pro-apoptotic role in head and neck squamous cell carcinoma 
(HNSCC), while CerS6 promoted growth of these cancer cells (Senkal et al., 2007). 
Additionally, CerS4 and CerS5 have been previously implicated in solid tumours such as 
breast cancer (Schiffmann et al., 2009). However, the precise roles of CerS4 and CerS5 in 
colon and endometrial cancers are unknown. Understanding the molecular mechanisms 
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underlying pathways involving CerS4 and CerS5 may significantly contribute towards 
improving anti-cancer-therapeutics. 
1.7 HYPOTHESIS 
Resistance to apoptosis is one of the hallmarks of cancer. CerSes (including CerS4 and 
CerS5) have been implicated in lung and breast cancer (Senkal et al., 2007; Panjarian et al., 
2008). However, little is known about the roles of CerS4 and CerS5 in endometrial and colon 
cancer. The hypothesis therefore states that CerS4 and CerS5 are involved in the apoptotic 
regulation of endometrial and colon cancers. Thus failure to properly regulate molecular 
mechanisms underlying these two genes may play a role in the development and the 
pathogenesis of endometrial and colon cancer. 
1.8 RESEARCH QUESTIONS 
• Do CerS4 and CerS5 interact with other proteins shown to be involved in apoptosis? 
• Are the expression levels of CerS4 and CerS5 affected in cancerous versus non-
cancerous cell lines? 
• Is there any relationship between apoptosis regulation and CerS4 or CerS5? 
• Does apoptosis induction modulate the expression levels of CerS4 and CerS5 in 
endometrial and colon cancer? 
1.9 BROAD OBJECTIVE 
The broad objective of this study was to determine the expression levels of CerS4 and CerS5 
in endometrial and colon cancers. 
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1.9.1 Specific-objectives 
• To determine the possible protein-interacting partners of CerS4 and CerS5. 
• To determine the expression levels of CerS4 and CerS5 in endometrial and colon 
cancer relative to non-cancerous (differentiated) cell lines using quantitative real-time 
PCR (qRT-PCR). 
• To induce, quantify and analyse apoptosis in endometrial and colon cells; and 
determine the expression levels of CerS4 and CerS5 in endometrial and colon cell 
lines after apoptosis induction. 
1.10 RESEARCH APPROACH 
The use of bio-informatics to study interactions (including protein-protein interactions) is 
growing (Prieto and De Las, 2010). Protein-protein interactions are essential in cellular 
events such as protein and vesicle trafficking, cell-cycle, signal transduction, gene expression 
and DNA repairs (Pawson and Nash, 2003). 
To address the research questions and objectives, we sought bio-informatics to determine 
CerS4 and CerS5 possible protein interacting partners. STRING, BioGRID and IntAct 
databases were used to identify the potential interacting protein partners of CerS4 and CerS5. 
Proteins involved in similar functions may share similar sequences and proteins with similar 
sequences may share similar functions (Sangar et al., 2007). This was then followed by 
determining sequence similarities between CerS4 and or CerS5 and their interacting partners. 
Following the bio-informatics analysis, gene expression analysis was done at mRNA level by 
qRT-PCR using CerS4 and CerS5 specific primers which were designed using Beacon 
Software (Bio-Rad). This was done to compare the expression level of CerS4 and CerS5 in 
endometrial and colon cancer relative to non-cancerous cells. 
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The change in expression level of CerS4 and CerS5 in endometrial and colon cancer lead to 
investigating the relationship of these genes and the apoptosis inducing drugs, anastrozole in 
endometrial cell lines and 5FU in colon cell lines. FACS was used to quantify and analyse 
apoptosis in endometrial and colon cell lines. Total RNA was extracted from treated and non-
treated cells. 
QRT-PCR was done to study CerS4 and CerS5 gene expression levels after apoptosis 
induction, since both of these genes were shown to be up-regulated in endometrial and colon 
cells, that is (i.e) before apoptosis induction. 
These findings implicate a role for CerS4 and CerS5 in the apoptosis regulation of 
endometrial and colon cancers. The next chapter outlines colon cancer and endometrial 
cancer, apoptosis as an essential process in cellular homeostasis and a background on 
Longevity Assurance genes, also known as CerSes, ceramide as a product of CerSes, and its 
implication in cancer biology. 
This thesis is structured in five chapters which are: The introductory chapter (Chapter 1); 
Chapter 2, which covers the Literature review; Chapter 3, outlining materials and methods; 
Chapter 4, showing results; and Chapter 5, which includes discussion and conclusion. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 CANCER, APOPTOSIS AND CERS4 AND CERS5 BACKGROUND 
Both CerS4 and CerS5 have been implicated in cancer biology. These two genes were found 
to be up-regulated in breast cancer and correlated with the pathogenesis of the disease 
(Schiffmann et al., 2009). Little is known about the precise roles of CerS4 and CerS5 in 
colon and endometrial cancer. 
2.2 ENDOMETRIAL CANCER 
Endometrial cancer is the most common of the female genital tract cancers and overall the 
fourth most common site for cancer to occur after breast, lung and colorectal cancers globally 
(Matsumoto et al., 2008). This cancer is one of the most common cancers seen in South 
African women (CANSA, 2012). The uterus is characterised by continuous cycles of 
endometrial cell growth and apoptosis in response to normal hormonal changes. The 
apoptotic pathway in female reproductive tissues generally involves a signal transduction 
pathway of a Fas receptor and its ligand rather than bax-bcl-2 pathway (Abe et al., 2006). Fas 
has been found to be expressed during the menstrual cycle. Estrogen and progesterone have 
been shown to control the expression of Fas, which is highly expressed during the secretory 
phase, suggesting a link with progesterone. Estrogen and progesterone represent the two 
survival factors in the human endometrium. Under the influence of estrogen, endometrial 
cells proliferate, partly as a result of the activation of anti-apoptotic genes and inhibition of 
the pro-apoptotic genes (Matsumoto et al., 2008). Progesterone on the other hand acts as a 
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differentiation factor, blocking mitosis and inducing terminal differentiation (Song et al., 
2002). Withdrawal of these hormones from endometrial cells has been shown to decrease cell 
viability and thus increase apoptosis, while studies of Fas-mediated apoptosis have shown 
that this death receptor is important for endometrial cycling and suggests that dysregulation 
of the Fas/FasL interactions may have an important role in the development of endometrial 
cancer (Wang et al., 2003). 
GMMe and Hec-1A endometrial cell lines 
In this study, two endometrial cell lines (non-cancerous GMMe and cancerous Hec-1A), were 
used. GMMe cells are cuboidal in shape and exhibit epithelial characteristics. The Hec-1A 
cell line is a human endometrial cancer cell line derived from a moderately adenocarcinoma 
differentiated tumour. This cell line does not produce matrix metalloproteinases (MMPs), 
which are responsible for the breakdown of extracellular matrix components, and are important 
in the metastatic phenotype (Schröpfer et al., 2010).  
2.3 COLON CANCER 
Colon cancer is one of the top five most prevalent cancers in both males and females, with 
the highest incidence found in developed countries such as Australia and New Zealand and 
the lowest incidence in developing countries, found in Africa and Asia (Jemal et al., 2011). 
However, over the past 20 years, the overall incidence of colon cancer in South Africa has 
been reported to have increased markedly and currently being in the top five of most common 
type of cancer in both males and females (Parkin et al., 2008; Cronje et al., 2009; CANSA 
2012). 
In normal healthy colon, cellular proliferation, lineage specification differentiation, migration 
and apoptosis are highly coordinated processes that occur in normally active colonic epithelial 
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cells. Failure to properly regulate these processes may lead to the development of colon 
cancer. Three important factors  contribute to the pathogenesis of colon cancer, including, the 
failure of colon epithelial cells to undergo apoptosis; secondly, a mutation in the p53 gene, a 
tumour suppressor gene involved primarily in cell cycle regulation and associated with 
initiating apoptosis (Huerta et al., 2006). A third possible factor is that Fas mutations are also 
associated with colon carcinomas (van der Woude et al., 2005; Garland et al., 2009).  
The Caco-2 cells and HT-29 colon cell lines 
Because of its great morphological, ultrastructural and biochemical similarity with small 
intestinal epithelial cells, the Caco-2 cell line has been used to represent a normal colonic cell 
line, to which the cancerous HT-29 colonic cell line was compared to (Sambuy et al., 2005; 
Geens and Niewold 2010). Normal colon cell lines (CCD-112CoN) have been reported to 
have a very short life-span and are difficult to maintain over a period of time under cell-
culture conditions (Larrosa et al., 2006). 
2.4 APOPTOSIS 
One of the hallmarks of cancer is the failure of cells to undergo apoptosis (Chaudhry and 
Asselin, 2009). Apoptosis, also named programmed cell death, is a normal component for 
cellular homeostasis involving embryonic/organ development and health in humans. For 
tumourigenesis, oncogenic factors are generally involved in activation of anti-apoptotic 
signaling pathways, whereas tumour suppressor factors are normally pro-apoptotic (Jin and 
El-Deiry, 2005). Studies of bio-active sphingolipids such as ceramide have gained attention 
over the past two decades for their important role in the regulation of multiple biological 
functions, especially in apoptosis. Apoptosis can be induced by adverse conditions such as 
cellular stress, cross-linking of death receptor, and exposure to anticancer drugs (Chaundry 
and Asselin, 2009). Apoptosis occurs through two main pathways, that is, extrinsic or death 
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receptor pathway and the intrinsic or mitochondrial pathway, shown in figure 2.1. Both 
pathways involve the activation of a cascade of proteases called caspases that interact with 
other proteins such as the Bcl-2 resulting in the death of the cell (Reed, 2000). Furthermore, 
apoptosis can also occur independently of caspases (Herbeuval et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 – Apoptosis signaling pathways:  In the death receptor (extrinsic) pathway, binding of 
death receptor ligands, e.g. CD95 and TRAIL ligands to death receptors, i.e. CD95 and TRAIL 
receptors triggers receptor trimerisation, recruitment of FADD and caspase 8 to DISC and activation 
of caspase 8 at the DISC. In the mitochondrial pathway, the release of cytochrome c from the 
mitochondria into the cytosol trigger caspase 3 activation, while Smac promotes apoptosis by 
neutralising Inhibitor of Apoptosis Proteins (IAPs), leading to apoptosis (Fulda, 2009). 
Activation 
Extrinsic/Death 
Receptor Pathway 
Intrinsic/Mitocho
ndrial Pathway 
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Upon induction of apoptosis, caspase 8 (which is present in most cell types as a proenzyme, 
in an inactive state) becomes activated via oligomerisation in a multimeric complex at 
activated death receptors (Mohr et al., 2005). The ligation of death receptors such as CD95 or 
TRAIL receptors, by their corresponding ligands, triggers receptor trimerisation and clustering 
of the receptors’ death domains which enables the recruitment of adaptor molecules such as 
Fas asscociated with a death domain (FADD) via protein-protein interactions through the 
death domains. Caspase 8 is in turn recruited to this complex via FADD through the interaction 
of the death-effector-domains (DED), which leads to the formation of the death-inducing 
signaling complex (DISC). This oligomerisation of caspase 8 in DISC drives its activation 
through autoproteolysis. Besides its proteolysis at the DISC, caspase 8 can also be activated 
downstream of the mitochondria upon initiation of the intrinsic apoptosis pathway (Cowling 
and Downward, 2002). Ceramide which can be produced de novo by ceramide synthases or 
the hydrolysis of sphingomyelin has been shown to induce apoptosis (Schiffman et al., 2009). 
Smyth et al., (1996) showed that Bcl-2 prevents ceramide-induced apoptosis, while Siskind et 
al., (2006) further demonstrated that exogenous ceramide initiates mitochondrial apoptosis by 
causing an increase of mitochondrial outer membrane permeability which allows cytochrome 
c release. Ceramide can be generated in mitochondria through sphingomyelin (SM) hydrolysis 
or de novo synthesis. Both mitochondrial-overexpressed sphingomyelinase and TNF-
stimulation leads to mitochondrial ceramide accumulation, Bax translocation, cytochrome c 
release, and apoptosis (Birbes, 2001 and 2005). In general, either exogenous ceramides or 
ceramide-generating death stimuli cause mitochondrial dysfunction, executor caspase 
activation, and apoptosis (Lin et al., 2007). Ceramide has also been shown to trigger apoptotic 
signaling through two additional pathways namely, the endoplasmic reticulum (ER) pathway 
and lysosomal pathways, shown in figure 2.2 (Huang et al., 2011). Conversely, more 
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investigations are needed to fully understand how ceramide triggers apoptosis in the latter 
pathways. 
 
Figure 2.2 - The pro-apoptotic role of ceramide:  Ceramide can trigger apoptosis through three 
different mechanisms which are: the mitochondrial pathway, the ER stress pathway and the lysosomal 
pathway. Adapted from (Huang et al., 2011). Ceramide generation can be through the hydrolysis of 
sphingomyelin or de novo synthesis by ceramide synthases, also known as longevity assurance genes, 
shown in figure 2.3. 
Ceramide is a building block of sphingolipids (SLs) (Ogretmen, 2006). Sphingolipids are 
major structural components of eukaryotic membranes and fulfill important cellular functions 
such as signal transduction and intracellular transport (Lahiri and Futerman, 2007; Becker et 
al., 2008). These molecules also play an important role in diverse processes important in 
cancer biology including apoptosis, cell proliferation, cell migration, senescence and 
inflammation (Ogretmen and Hannun, 2001; Futerman and Hannun, 2004). These 
sphingolipid-regulated processes are in turn, crucial in cancer development and progression, 
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and may also influence the efficacy of anti-cancer therapeutics (Reynolds and Kolesnick, 
2004; Fox et al., 2006; Modrak et al., 2006). A key step in the de novo synthesis of 
sphingolipids is the synthesis of dihydroceramide by (dihydro)ceramide synthases (CerS). 
Ceramide can also be produced by the hydrolysis of sphingomyelin (SM), which is one of the 
SLs. In the de novo pathway, CerS catalyses the transfer of acyl residues from acyl-CoA to 
sphinganine, thereby forming dihydroceramide. Dihydroceramide is then converted to 
ceramide by dihydroceramide desaturase. Ceramide can be further used as a precursor for the 
synthesis of other SLs (Futerman and Riezman, 2005). Figure 2.3 illustrates the synthesis of 
ceramide. 
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Figure 2.3 - Schematic diagram of ceramide metabolic pathway:  This pathway starts by the 
condensation of Palmitoyl-CoA with serine by serine palmitoyl transferase. The main product of this 
pathway (ceramide), can be further converted to sphingomyelin by sphingomyelinase or broken down 
to sphingosine by ceramidase (Levy and Futerman, 2010).  
Much has been reported on ceramide produced through SM hydrolysis, compared to reports 
on ceramide produced de novo. However, this area of research is growing. In addition, little is 
known about the interaction or the relationship between the two pathways that produce 
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ceramide. Furthermore, CerSes have been implicated in cancer development, progression and 
metastasis. 
2.5 LONGEVITY ASSURANCE GENES (LASS)/CERAMIDE 
SYNTHASES (CERS) 
Longevity assurance genes or Ceramide Synthases are a family of related genes. This family 
of genes was first discovered in yeast cells and the members are highly conserved as seen in 
bacteria and humans. (Pewzner-Jung et al., 2006; Masukawa et al., 2008; Mizutani et al., 
2009; Levy and Futerman 2010). To date, at least six paralogs have been identified in mice 
and humans and at least two members of this gene family have been found in every organism 
studied so far, as seen in figure 2.4. In yeast, longevity assurance genes are designated LAGs, 
in mice Lass and LASS in humans. In all LASS family members, LASS1 is most closely 
related to yeast proteins, while LASS2 to 6 are closely related to each other, as shown in 
figure 2 (Mizutani et al., 2006 and 2009). 
 
Figure 2.4 - Phylogenetic Tree of Longevity Assurance Genes:  This figure shows LASS1 as being 
furthest from LASS2-6, with LASS 5 and 6 being closely related and furthest from LASS 1. LASS 2 
and LASS 3 are shown to share a common origin and LASS 4 being most closely related to LASS2. 
Adapted from Mizutani et al., (2006). 
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Human and mouse orthologs have been found to have strong similarities, both in sequence 
and genomic structure (Pewzner-Jung et al., 2006). CerS belongs to a large family of 
endoplasmic reticulum (ER) membrane-associated proteins (Mizutani et al., 2006 and 
Pewzner-Jung et al., 2006). Both human and mouse proteins contain two major domains, the 
Hox domain and the Tram-Lag-CLN8 (TLC) domain as shown in figure 2. 5. 
 
Figure 2.5 - The amino acid conservation of the LASS genes:  The two major conserved domains in 
LASS proteins, the homeobox domain in blue and the TLC domain in orange. The numbers represent 
the amino acid residues. LASS1 is the shortest isoform due to the absence of the Hox domain. LASS 
2-6 contain 30 to 44 amino acids more (Mizutani et al., 2006). 
The hox domain is derived from homeobox proteins that usually are sequence specific 
transcription factors regulating development (Venkataraman et al., 2002). In LASS genes 
however there is no evidence to suggest that the Hox domain acts as a transcription factor 
(Pewzner-Jung et al., 2006). To date, in humans, it has been shown that all members of the 
LASS family except for LASS3 encode at least two isoforms (Pewzner-Jung et al., 2006). 
The longer isoform retains both domains, TLC (in orange) domain and the Hox (in blue) 
domain, while the shorter isoform lacks the hox domain as well as part of the TLC domain, as 
seen in figure 2.6. 
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Figure 2.6 - Difference between the isoform 1 and isoform 2:  This figure illustrates the difference 
between the shorter and the longer isoform of LASS genes. The longer isoform retains the two domains 
while the shorter isoform lacks the Hox domain and part of the TLC domain (Ogretmen, 2006). 
It has been reported that the two isoforms seem to be involved in similar mechanisms of 
transcriptional regulation, suggesting that the Hox domain is not critical for these proteins to 
function (Pewzner-Jung et al., 2006; Ogretmen, 2006; Levy and Futerman, 2010). It has also 
been documented that the TLC domain is crucial for the main function of LASS proteins, 
which is the synthesis of ceramide (Ogretmen, 2006; Mizutani et al., 2006 and 2009). In 
addition, the CerS TLC domain consists of a highly conserved Lag1p motif of ~52 amino 
acids which is essential for the CerS catalytic activity (Spassieva et al., 2006; Teufel et al., 
2009). Furthermore, the Lag1p motif renders CerSes unique from other TLC domain 
containing proteins which do not produce ceramide (Teufel et al., 2009). 
2.5.1 LASS genes and their functions 
As mentioned above, LASS genes mainly produce ceramide, and different LASS genes are 
specific for different ceramide species. LASS4 (previously known as Trh1) and LASS5 
(formerly known as Trh4) were the first members of the LASS family to be discovered to 
produce ceramide (Pewzner-Jung et al., 2006). The ceramide molecule consists of a 
sphingoid long chain base linked to a fatty acid chain by an amide bond and the ceramide 
structure is shown in figure 2.7. 
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Figure 2.7 - Structure of a ceramide molecule:  Ceramide contains a long saturated carbon chain 
base linked to sphingosine. Adapted from Ogretmen (2006). 
The sphingoid base is the same on all ceramide molecules produced by CerSes, but these 
ceramide molecules differ in fatty acid chain length (Lahiri et al., 2007). Some CerSes may 
share substrate preference, for example, CerS5 and CerS6 both share C-16 fatty acid chain, 
while others are shown to have a broad substrate specificity, for example, CerS2 (Mizutani et 
al., 2005 and 2006; Laviad et al., 2008; Saddoughi et al., 2008). Table 2.1 shows CerSes and 
their substrate preferences. 
 
Table 2.1:  The CerS family members with their different substrate preferences 
CerS member Substrate preference 
CerS1/LASS1 C18:0 
CerS2/LASS2 C20-C26 
CerS3/LASS3 C22-C26 
CerS4/LASS4 C18-C20 
CerS5/LASS5 C16 
CerS6/LASS6 C14 and C16 
 
In addition, CerS1-6 have also been shown to have preferential tissue specificity (Mizutani et 
al., 2006; Laviad et al., 2008). 
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2.5.2 Tissue Distribution of LASS Gene Product/CerS 
As membrane components, CerS have both the N and C- termini located on the cytosolic 
leaflet, demonstrated as in figure 2. 9. LASS1 is found predominantly in the brain and LASS5 
is found predominantly in lung epithelia (Xu et al., 2005; Laviad et al., 2008). C-16-
ceramides are also found in non-neuronal tissues such as lung, liver and colon and in 
fibroblasts, endothelial cells and cells of the immune system. LASS5 has also been 
implicated in prostate cancer (Eto et al., 2003). Additionally, LASS3 is found to be highly 
expressed in testis, whereas LASS2 was shown to have a broad tissue distribution (Ogretmen, 
2006; Levy and Futerman, 2010). Generally little is known about LASS genes and the 
products with regard to expression levels in different tissues. Furthermore, it has been 
reported that CerSes can be modified at a posttranslational level, and this posttranslational 
modification plays a role in cell fate (Stiban et al., 2010). 
2.5.3 Posttranslational Modification of LASS Gene Products/CerS 
There is accumulating evidence to suggest that the CerS family members may undergo 
posttranslational modification through phosphorylation. Activation of Protein Kinase C 
(PKC) has been shown to increase the phosphorylation of CerS, and thus increase de novo 
ceramide synthesis, leading to cell death (Becker et al., 2005; Kitatani et al., 2006). Calcineurin 
in turn antagonises the phosphorylation of ceramide, and thus promotes proliferation (Stiban 
et al., 2010), as shown in figure 2.8. However, little is known about the CerSes 
phosphorylation sites. Additionally, the mode of action of ceramide regarding the cell fate 
depends on the downstream targets of ceramide (Ogretmen, 2006). 
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Figure 2.8 - The posttranslational modification of ceramide:  The phosphorylation of PKC by ATP 
in cells increases the production of ceramide through CerS phosphorylation. Contrary to CerS 
phosphorylation, calcineurin dephosphorylates CerS, and thus leads to decreased ceramide production. 
Depending on the ceramide species and type of tissue, increased or decreased CerS activity can either 
lead to cell death or cell proliferation (Stiban et al., 2010). 
2.5.4 The mode of action of ceramide 
The summary of ceramide mode of action is illustrated in figure 2.9. Ogretmen (2006) found 
that upon various stimuli, ceramide synthesis is activated by either a de novo pathway or 
hydrolysis of SM (1) (sphingomyelin). Ceramide regulates the anti-proliferative responses of 
cells by regulating its downstream targets such as caspases and telomerases (2). Alternatively, 
ceramide can be converted to SM, sphingosine-1-phosphate (S1P), sphingosine and 
glycosylceramide, yielding diacylglycerol (DAG) as a byproduct (3). This reverse pathway of 
ceramide results in cell survival processes such as drug-resistance (4), malignant 
transformation (5), cell migration and cell proliferation, including blood vessel formation. 
This reverse process of ceramide to anti-apoptotic molecules such as S1P (6) occurs through 
the activation of sphingosine-1-phosphte and its receptor and involves the activation of ERK, 
PKC 
CerS Activity 
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NF-κB (7), while inhibiting caspases and (8) BAX (which is a pro-apoptotic protein). In 
addition, enzymes which regulate ceramide levels such as ceramidases, exert opposing effects 
on ceramide and thus increase cell survival by their anti-apoptotic function (Ogretmen, 2006). 
Furthermore, c-myc (9) and cyclins (and cyclin dependent kinases) were also shown to be 
downstream targets of the Wnt signaling pathway.  
 
Figure 2.9 - The mode of action of ceramide:  Ceramide can either activate or inactivate its 
downstream targets to induce apoptosis in cells, as described in section 2.5.4 (Ogretmen, 2006). 
Interestingly, c-myc and cyclins (and cyclin dependent kinases) were shown to be (indirect) 
downstream targets of both LASS genes and their products and the Wnt signaling pathway. 
Targeting the Wnt signaling pathway may help in understanding molecular functions of 
LASS genes and the impact they have in cancer biology. Furthermore, CerSes have been 
implicated in other diseases. 
4 5
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2.5.5 The implication of ceramide in diseases 
De novo ceramide synthesis has also been implicated in a number of diseases, such as diabetes 
(Summers 2006), Cystic Fibrosis, (Ito et al., 2004; Vilela et al., 2006) and chronic obstructive 
pulmonary disease (COPD) (Petrache et al., 2005 and 2006). Ceramide may also play a role 
in Alzheimers disease where the long ceramide carbon chains abundant in some regions of 
the brain are vulnerable to Alzheimer’s disease (Cutler et al., 2004; Wang et al., 2008). 
Ceramide has also been shown to be involved in neuronal death (Schwarz and Futerman, 1997) 
and white matter dysfunction, cerebral ischemia and stroke (Yu et al., 2000; Jana and Pahan, 
2004; Lee et al., 2004). 
The generation of ceramide through SM hydrolysis has been shown to be linked with colon 
cancer (Wu et al., 2004). Loss-of-function mutation of Alkaline Sphingomyelinase (Alk-
SMase) has been shown in colon cancer HT-29 cells (Wu et al., 2004) and in liver cancer 
HepG2 cells (Cheng et al., 2007). The Alk-SMase mutation in HT-29 colon cells occurs at 
the alternative splicing level, involving the deletion of exon 4, which encodes a critical His 
(Histidine) that participates in the formation of binding site for SM (Zalatan et al., 2006). 
This evidence suggests the direct effect of ceramide in colon cancer, produced through the 
hydrolysis of SM, but what exactly is the role of ceramide produced de novo by CerS in colon 
cancer is still unclear. 
While SM, ceramide and sphingosine have antiproliferative and proliferative effects in colon 
cancer cells, S1P has specifically been shown to stimulate cell proliferation, inhibit apoptosis 
and promote inflammation, cell migration and angiogenesis. In colon cancer, high levels of 
S1P correlate to a poor survival rate (Van Brocklyn et al., 2005). In colon cancer cells, S1P 
has been shown to induce COX 2 expression (Hsieh et al., 2006), and activate p38, MAPK 
and Erk (Thamilselvan et al., 2002). S1P also increase the production of PDGF and VEGF 
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and activate growth factor receptor. Visentin et al., (2006) showed that neutralising S1P with 
specific antibody significantly inhibited the cancer progression through inhibiting the cell 
proliferation and blocking neovascularisation in several cell lines including HT-29 colon 
cancer cells. Additionally, sphingosine kinase (Sphk), the enzyme responsible for the 
formation of S1P, is upregulated in many cancer tissues including colonic adenocarcinoma 
(Kawamori et al., 2006). Furthermore, ceramide generated de novo has been shown to induce 
apoptosis through Tumour Necrosis factor α (TNF α) in colon cancer cells as a result of the 
of the cannabiniod receptor activation. However, the study did not specify which CerS was 
responsible for the apoptosis induction (Cianchi et al., 2008). A balance between ceramide 
and S1P has been considered as a rheostat mechanism that may determine cell death and cell 
survival. The normal intestinal epithelial cells have high levels of S1P lyase and S1P 
phosphatase. However, in colon cancer cells, both S1P lyase and S1P phosphatase are down 
regulated and thus the catabolism of S1P is inhibited (Duan and Nilsson, 2009). Additionally, 
ceramide has also been implicated in other types of cancer, including endometrial cancer. 
Reports implicating ceramide in endometrial cancer are limited. However, it was demonstrated 
by Knapp et al., (2010) that SL metabolism in the human endometrial carcinoma is markedly 
elevated compared to the healthy endometrium. They showed that the human endometrial 
cancer is characterised by increased of ceramide compared to normal endometrium. In addition, 
they demonstrated that increased levels of ceramide in endometrial cancer were accompanied 
by high rates of the de novo ceramide synthesis pathway. Furthermore, they also showed that 
endometrial carcinoma was also characterised by increased levels of sphingosine 1 phosphate 
(S1P). The role of CerSes in limited response of endometrial cancer chemotherapy was also 
highlighted by Knapp et al., (2010), by indicating that doxorubicin and cisplatin (which are 
commonly used to treat the metastatic endometrial cancer) are largely dependent on the 
increase levels of intracellular ceramide, including the stimulation of the de novo synthesis 
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pathway. New approaches to improve the response of endometrial cancer cells to chemotherapy 
are needed as it has been demonstrated that endometrial cancer is characterised by elevated 
levels of ceramide, at least in part from the de novo pathway. (Noda et al., 2001; Min et al., 
2007; Rath et al., 2009; Knapp et al., 2010). However, unlike in colon cancer, the ratio between 
S1P and ceramide in endometrial cancer was shown to be stable. 
To date, LASS genes have been implicated in cell regulation through the production of 
ceramide. But the role that these different ceramide species play in cancer development and 
progression remains to be elucidated. Thus, at present, it is difficult to draw definitive 
conclusions concerning the role of particular ceramides in defined physiological and 
pathophysiological events. However, the possibility to experimentally manipulate LASS 
genes and study their expression, will aid in better understanding the precise roles of specific 
ceramide species, in different tissues. So far six human CerS have been discovered and their 
substrate specificity in terms of synthesising ceramides is known. However, the role these 
ceramide species play in different cancers remains unclear. To complicate matters, it has been 
shown that the same ceramide species can exert opposing roles in different cancers. (Karahatay 
et al., 2007; Senkal et al., 2007). Thus it seems reasonable to investigate the roles of CerS4 
and CerS5 in colon and endometrial cancers. The next chapter outlines the materials and the 
methods used to achieve our goal, as indicated in section 1.7. 
 
  
 
31 | P a g e  
CHAPTER 3 
MATERIALS AND METHODS 
3.1 MATERIALS 
Human colon cell lines, Caco-2 and HT-29 were purchased from Highveld Biological (Pty) 
Ltd (Johannesburg, South Africa). Human endometrial cell lines, GMMe and Hec-1A were 
purchased from the American Type Culture Collection. 
3.1.1 Endometrial Cell lines 
3.1.1.1 GMMe cell line 
GMMe cell line was established by the stable transfection of endometrial tissue of an adult 
female mink. A plasmid vector encoding simian virus 40 (SV40) large T-antigen driven by 
the human β-actin promoter, was used for transfection. The cells were cotransfected with a 
second plasmid vector to confer neomycin resistance and were selected in medium containing 
G418. GMMe cells are cuboidal in shape and exhibit epithelial characteristics. This cell line 
has also been shown to be positive for alkaline phosphatase (www.atcc.org). 
3.1.1.2 Human Endometrial cell line-1A (Hec-1A) cell line 
Hec-1A is an endometrial epithelial adenocarcinoma cell line, derived from a moderately 
differentiated tumour. This cell line does not produce matrix metalloproteinases (MMPs), 
which are responsible for the breakdown of extracellular matrix components, and are important 
in the metastatic phenotype (Schröpfer et al., 2010).  
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3.1.2 Colon cell lines 
3.1.2.1 Caco-2 colon cell line 
The study of normal colon cell maturation has been hindered by the inability to maintain 
normal colonic epithelium cells in culture. For this reason, model systems such as the highly 
differentiated Caco-2 cell line have proved to be a suitable and highly informative alternative 
for such studies. (Sambuy et al., 2005).  
3.1.2.2 HT-29 colon cell line 
HT-29 colon cells are highly malignant and poorly differentiated. It has been shown by Wu et 
al., (2004) that these cells have an exon 4 deletion of alkaline sphingomyelinase (alk-SMase) 
gene transcript. This enzyme catalyses the hydrolysis of sphingomyelin (SM) to ceramide. 
3.1.3 Primer sequences for LASS4, LASS5 and β-actin 
Specific primers were designed using the (Beacon software Bio-Rad) to amplify LASS4, 
LASS5 and β-actin from the synthesised cDNA. The mRNA variant 1 sequences were 
obtained from NCBI website LASS4 NM_024552.1, LASS 5 NM_147190.1 and β-actin 
NM_001101.3. The primer sequences were then sent to Inqaba Biotec (SA) for synthesis and 
100 µM stocks were dissolved in 1XTE. 10 µM dilutions were prepared as working solutions. 
Table 3.1 shows the primer sequences for LASS4, LASS5 and β-actin.  
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Table 3.1: The primer sequences and product sizes for LASS 4, LASS 5 and β-actin 
  Amplified gene      Sequences    Product 
size 
Annealing 
Temperature 
Melting 
Temperature 
              LASS 4        
 
Fw: ctctggtgctgctgttac 
Rv: 
gactcgtagtatgtggtgtag 
       175bp 53°C 83°C 
             LASS 5 Fw: atggtggctcctcaatgg 
Rv: aggtggtcacatcttcttcc 
       124bp 55°C 84°C 
             β-actin Fw: 
gcgggaaatcgtgcgtgacatt 
Rv: 
gatggagttgaaggtagtttcgtg 
       232bp 54°C 89°C 
 
3.1.4 Apoptosis induction 
The cells were serum starved for 24h for synchronisation prior to treating with apoptosis 
drugs (Cooper 2003). Apoptosis was induced in colon and endometrial cells, and then 
fluorescence-activated cell sorter (FACS) was used to analyse and quantify apoptosis. 
3.1.5 Flow Cytometry (FCM)/ fluorescence-activated cell sorter (FACS) 
Flow cytometry is an analytical tool that allows for the discrimination of different particles on 
the basis of size and colour. In this study, flow cytometry, the Flow cytometer Beckton 
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Dickson Facs Calibur was used to detect apoptosis, differentiating between live and dead 
cells. The Annexin V kit (BD-BioSciences, USA) was used. 
3.1.5.1 Probes for Flow Cytometry 
A number of fluorescent probes have been developed for the analysis of cycling cells through 
flow-cytometry. These include propidium iodide (PI) and Annexin V-Fluorescein 
isothiocyanate (FITC). The loss of plasma membrane is one of early apoptotic features, in 
apoptotic cells. The membrane phospholipid phosphatidylserine (PS) is exposed from the 
inner to the outer leaflet of the plasma membrane, thereby exposing the PS to the external 
cellular environment. Annexin V is ~36KDa Ca2+ dependent phospholipid-binding protein 
that has high affinity for PS, thus binds to cells with exposed PS. Annexin V may be 
conjugated to fluorochromes such as FITC. This conjugation retains high affinity for PS and 
thus Annexin V-FITC serves as a sensitive probe for identifying apoptotic cells. Therefore 
cells that are in early apoptosis are Annexin V-FITC positive. 
PI on the other hand is a fluorescent nucleic acid dye, which stains the total cellular DNA 
content. PI intercalates into the DNA double helix of fixed and permeabilised cells, but does 
not cross the intact plasma membrane of viable cells. Furthermore, the dye (PI) can readily 
enter dead cells, cells in late apoptotic stages, or fixed cells with damaged plasma membrane. 
Annexin V-FITC staining is usually used in conjunction with PI staining to permit the 
identification of cells that are in early apoptosis. Viable cells are Annexin V-FITC and PI 
negative. Early apoptotic cells are Annexin V-FITC positive and PI negative. Cells that are in 
late apoptotic stages or already dead stain for both Annexin V-FITC and PI positive. 
NB:  For each cell line, the following were prepared, blank which constituted of only viable 
unstained cells. A negative control was composed of untreated but stained cells. These controls 
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were run in conjunction with the experiment of treated cells. The blank is used to gate the 
cells with forward and side scatter. The negative control is important in obtaining the true 
apoptotic signal from the false signal.  The DMSO control was not considered necessary as it 
has been previously shown that it (DMSO) does not influence the cytotoxic effects of 
anastrozole (Wang and Chen, 2006). The vertical and the horizontal gates of the experiment 
were placed in the same position as those of the controls. 
3.2 METHODOLOGY 
Methodology was divided into two sections, the bio-informatics and the gene expression 
section. 
3.2.1 Bio-informatics 
3.2.1.1 STRING database and Multi-Align Tool 
The use of bio-informatics to discover disease causing genes and how these genes and their 
products are regulated is growing. As CerS4 and CserS5 have been previously implicated in 
cancer biology, especially apoptosis, STRING protein-protein interaction database was used 
to determine CerS4 and CerS5 possible interacting partners and examine if these proteins 
may be involved in similar cellular functions as CerS4 and CerS5, such as apoptosis. Following 
this, the amino acid sequences of the possible interacting partners for both CerS4 and CerS5 
were obtained from STRING database and verified using NCBI. CerS4/CerS5 and its potential 
interacting partners’ amino acid sequences were aligned using Multi-Align tool, by randomly 
pasting the amino-acid sequences of these proteins. This was done to examine sequence 
similarity between CerS4, CerS5 and their protein interacting partners. 
In addition to the STRING database, BioGRID and IntAct databases were used to determine 
protein-protein interactions. Furthermore, Clustal omega and COBALT were used in 
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conjunction with the Multi-Align database to examine sequence similarity between 
CerS4/CerS5 and their interacting partners. 
NB: 
• STRING database protein interactions are experimentally determined as well as 
predicted interactions. 
• IntAct database protein interactions are experimentally determined. 
• Bio-GRID database provides comprehensive information (including experimentally 
determined) protein interactions. 
3.2.2 Gene expression analysis 
3.2.2.1 Cell culture 
The cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM), or 
HAM’S-F-12 supplemented with 10% fetal bovine serum (FBS) and 1% streptomycin in a 
humid atmosphere containing 95% air and 5% CO2 at 37 ºC until the cells reached a required 
confluency. The cells (1X106 cells/ml) were further sub-cultured by trypsinisation, using 
trypsin-EDTA (Sigma-Aldrich), until 70% confluency was reached. Five (5)-Fluorouracil 
inhibits Thymidylate synthatase, which is a crucial enzyme for DNA synthesis, was then 
added to the medium, to induce apoptosis, in colon cell lines for 24h and 48h. Anastrozole, 
which is an aromatase inhibitor, was used to induce apoptosis in endometrial cell lines for 
24h. The cultured cells were used for flow cytometry and for RNA extraction. 
3.2.2.2 FACS analysis 
Apoptosis was induced using apoptosis inducing drugs in colon and endometrial cell lines. 
Five (5 µM) of 5-Fluorouracil (5-FU) was used to induce apoptosis as demonstrated by Thant 
et al., (2008) to be cytotoxic and was therefore used to induce apoptosis in Caco-2 and HT-29 
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colon cell lines. Anastrozole has also been shown to induce apoptosis in endometrial cancer 
(Burnett et al., 2004). Meresmas et al., (2005) further demonstrated that anastrozole can 
induce apoptosis in endometrial cell lines from 50nM over 48 hrs, or increased anastrozole 
concentration over a short period of time. In this study, 2 µM anastrazole was used to induce 
apoptosis in GMMe and Hec-1A endometrial cell lines. Cells were incubated for a period of 
0–48 hrs and the Annexin V-FITC apoptosis detection kit I was used for FACS analysis, with 
appropriate filter sets (excitation at 488nm; emission at 530nm).   
The following controls were used to set up compensation and quadrants: 
• Unstained cells 
• Cells stained with Annexin V-FITC alone (no PI) 
• Cells stained with PI alone (no Annexin V-FITC) 
• Both fluorochromes (Annexin V-FITC and PI) were added in one tube and the results 
were analysed with flow-cytometry. 
The Flow Cytometry set-up was as follows: 
Different cell lines were maintained and incubated to undergo apoptosis and were trypsinised. 
This was followed by centrifuging at 2000 xg 5 min. Then the pellet was washed with 1 ml 
1X PBS twice and resuspended in 200 µl of 1X binding buffer. 100 µl of each solution was 
transferred into a 5 ml tube. Then 5 µl of Annexin-FITC and PI were added to different tubes. 
The cells were then gently vortexed and incubated in the dark at room temperature (25 ºC) for 
15 min. 400 µl of 1X binding buffer was then added to each tube and the results were 
analysed by flow cytometry. Results were represented in a cytogram and figure 3.3 shows a 
representative cytogram. 
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Figure 3.3 - A representation of a cytogram for FACS analysis:  Quadrant number 1 constituting 
of viable cells (Annexin V and PI negative), 2 with cells undergoing early apoptosis (Annexin V 
positive and PI negative), and 3 with late apoptotic and necrotic cells. 
Total RNA was extracted from treated and untreated cell lines. 
3.2.2.3 RNA extraction 
Prior to cDNA synthesis for quantitative real-time PCR (qRT-PCR), total RNA was extracted 
from the cultured cells. This was done using the AurumTM Total RNA Mini Kit (Bio-Rad, 
USA), following the manufacturer’s guide. The floating cells were collected and the adherent 
cells were washed with 1X PBS and were treated with trypsin-EDTA to detach them from the 
growth vessel. After the trypsin was poured out, the vessel was then rinsed once with 200 µl 
of PBS. This was then transferred into a 2 ml microcentrifuge tube and centrifuged for 2 min. 
The supernatant was discarded and 350 µl of the lysis solution (supplemented with 1% β-
mercaptoethanol) was added to each tube. This was pipetted at least 12 times up and down to 
lyse the cells thoroughly. To this 350 µl of 70% ethanol was added to each tube and was 
mixed thoroughly by pipetting up and down. The elution solution was then placed into a 
70 ºC bath to warm it and use at a later stage. The RNA binding columns (provided) were 
inserted into 2 ml capless wash tubes and the homogenised lysate was then transferred into 
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the RNA binding columns. This was centrifuged for 30 sec and the filtrate was removed from 
the wash tube after removing the binding column. The binding column was then replaced into 
the same wash tubes. The low stringency wash solution (provided as 5× concentrate, to which 
95–100% ethanol was added) was added to the RNA binding column, 700 µl. Following this, 
the RNase-free DNase I provided as powder was reconstituted by adding 250 µl of 10mM 
Tris, pH 7.5. Then 5 µl of the reconstituted DNase I was mixed with 75 µl of DNase dilution 
in a sterile 1.5 ml microcentrifuge tube. The diluted DNase was then added (80 µl) to the 
membrane stack, to the bottom of each column. This was then incubated at room temperature 
(RT) for 15 min, to allow the digest. The columns were centrifuged for 30 sec when the 
digest was complete and the digest buffer was discarded and the column was replaced into 
the same wash tube. To this 700 µl of high stringency wash solution was added and 
centrifuged for 30 sec. The column was replaced into the wash tube after discarding the 
filtrate. Then 700 µl of the low stringency wash solution was added to the RNA binding 
column and centrifuged for 1 min. The low stringency wash solution was discarded and 
column was replaced into the same tube. This was then centrifuged for another 2 min to 
remove the residual wash solution. The columns were then transferred into sterile 1.5 ml 
capped microcentrifuge tubes and 80 µl of the warmed elution solution was pipetted onto the 
membrane stack at the bottom of the RNA binding column. This was incubated for 1 min at 
RT to allow the solution to saturate the membranes. This was then centrifuged for 2 min to 
elute the total RNA. The eluted total RNA samples were then stored at -80°C for later use. 
The extracted RNA was then used for reverse transcription.  
 
40 | P a g e  
3.2.2.4 Reverse transcription or cDNA synthesis 
Reverse transcription is the technique that synthesises the complementary deoxyribonucleotide 
nucleic acid (cDNA) from the RNA template. This process uses reverse transcriptase, which 
reverse transcribes mRNA into cDNA. 
A Promega ImPromTM - II Reverse Transcriptase System (A3802) was used to synthesise 
cDNA from total RNA from the cell lines. The manufacturer’s instructions were followed. A 
total of 1 µg RNA was used as the template for reverse transcriptase. The reverse transcription 
reaction was carried out in a total volume of 20 μl per RNA sample, and the composition of 
the reagents is shown in Appendix 2, table 2a. Table 2b shows the conditions for cDNA 
synthesis. The synthesised cDNA was used for PCR. 
3.2.2.5 Polymerase Chain Reaction (PCR) 
PCR is a method used to amplify DNA segments through repetitive cycles of DNA synthesis. 
This process is made possible by the Taq Polymerase which utilises free floating 
oligonucleotides in reaction solution. Specific primers are required to amplify the fragment of 
interest as they bind to cDNA through base complementarity to guide the polymerase as to 
where to begin synthesis. The PCR technique involves 3 temperature steps known as 
denaturation: where the double stranded cDNA is separated out into single strands to allow 
binding of primers; annealing: in this step, the primers anneal to the single stranded DNA 
through base complementarity guiding the polymerase as to where it should start synthesising 
and elongation: where the amplified products are lengthened to reach the exact size of the 
fragment of interest. 
In addition, as an in vitro technique, there can be a number of factors that contribute to the 
success of PCR. These include pH, salt concentration, temperature and primer: template ratio. 
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In this investigation, the reagent concentrations and temperatures were optimised in such a way 
as to allow the optimal conditions and ensure the success of the PCR. The PCR composition 
reaction is shown in table 2c, and the conditions are shown in table 2d, Appendix 2. 
3.2.2.6 Agarose gel electrophoresis 
Agarose gel electrophoresis is the technique by which DNA can be separated according to its 
size. The nucleic acid material is loaded onto the formaldehyde agarose gel, to which an 
electric current is applied. The DNA migrates towards the positive electrode due to its negative 
charge rendered by its phosphate molecules on its backbone. The agarose gel, which contain 
randomly distributed pores acts as a “molecular sieve”, separating the molecules by size. The 
DNA fragments are visualised by staining the gel with ethidium bromide. Ethidium bromide 
intercalates between the bases of the DNA, which can then be visualised under UV light. 
Preparation of 1% agarose gel 
This was done to determine the success of PCR and if successful, determine the size of the 
PCR product. A 1.0% agarose gel was prepared by heating 1.0 g of agarose powder in 100 ml 
of 1X Tris Borate EDTA (TBE), in a microwave until all powder had dissolved. The mixture 
was cooled to 4 ºC and 3.5 µl (100 µg/ml) of EtBr was added and mixed. The mixture was 
poured into a gel casting tray, combs inserted and allowed to set. The PCR products were 
loaded on the wells and run parallel to a 50bp molecular weight marker in 1X TBE buffer at 
70V for 1 hr. The molecular weight marker was loaded for size determination. After running, 
the gel was viewed using a Bio-Rad Gel. Doc system and the results are shown in the results 
section. 
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To verify that the primers had amplified the regions of interest, the PCR products were then 
cloned into a p-GEM-T-Easy vector (Appendix 2, figure 2a), as described in section 3.2.2.7 
below, and then sent for sequencing. 
3.2.2.7 Cloning 
Cloning is the technique by which the DNA segment of interest is inserted into an 
autonomously replicating DNA molecule (cloning vector) so that the DNA segment of 
interest is replicated with the vector. Cloning involves two steps: ligation and transformation. 
Ligation 
Ligation is the technique by which recombinant DNA (rDNA) molecules are constructed by 
joining together the vector molecule and the DNA segment of interest using DNA ligase 
usually, T4 DNA ligase. 
The PCR products were ligated into pGEM-T-Easy vector, figure 2a. p-GEM-T-Easy (shown 
in Appendix 2) vectors are convenient vectors by which PCR products can be cloned into. 
These vectors are prepared by cutting pGEM-T Easy vectors with EcoRV restriction enzyme 
and adding 3’ terminal thymidines (T) to both ends. These 3’ T overhangs at the insertion site 
improves the efficiency of ligation of a PCR product into plasmids by preventing recircularisation 
of the vector and providing a compatible overhang for certain thermostable polymerases that 
often add a single adenosine (A), in a template-independent fashion, to the 3’ ends of the 
amplified fragments. Thus, the vector has T tails that can be ligated to the A overhangs of 
Taq polymerase PCR reaction products. 
The ligation reactions were carried out using the LigaFastTM Rapid Ligation System (Promega 
Corporation, Madison WI, USA). Ligation reactions were carried out in a total volume of 10 
μl consisting of the reagents indicated in table 2e, Appendix 2. One control was used, a 
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negative control, where nuclease free water was added instead of the PCR product, all the 
other ingredients were added. These reactions were then incubated at room temperature for 
three hours after which transformation was performed. 
Transformation 
Transformation is the technique that ultimately allows for the selection and propagation of 
plasmid DNA via competent bacterial cells taking up the plasmid DNA. Positive selection for 
bacterial cells containing the plasmid DNA is accomplished by growth on medium containing 
an appropriate antibiotic, since the plasmid DNA is engineered to contain the corresponding 
antibiotic resistant gene. 
Preparation of Competent Cells 
Normally Escherichia coli cells do not possess the ability to take up DNA from the 
environment. However, if their cell walls are altered, these bacterial cells become more likely 
to incorporate foreign DNA and thus these cells are said to be ‘competent’. These cells can be 
made competent by chemical or physical treatment. Chemical treatment includes the calcium 
chloride method while a physical treatment includes electroporation whereby the bacterial 
cell is shocked with 2500 V. 
The chemical treatment method was used in order to make MC1061 Escherichia coli cells 
(Fermentas Life Sciences, Hanover, MD, USA) competent. These cells were used for cloning 
of the LASS4 and LASS5 fragments. 
1. The night before making competent cells the desired bacterial (MC1061 Escherichia 
coli) strain was plated on Luria-Bertani (LB) Broth plates containing 10 mM Magnesium 
Chloride (MgCl2). 
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2. A single colony of the desired strain was added to 20 ml Tryptone Yeast Extract MgCl2 
(TYM) Broth in a 500 ml conical flask and grown at 37 ºC overnight, shaking constantly 
at 300 xg. 
3. 1 ml of cells in the TYM Broth were added to 100 ml fresh TYM Broth in a 2 L conical 
flask. The cells were grown for a further 2–3 hours or until optical density at 550 nm 
equals 0.2 at 37 ºC, shaking constantly at 300 xg. 
4. Thereafter, 400 ml of fresh TYM broth was added to the 2 L conical flask and cells allowed 
to grow for a further 2–3 hours or until optical density at 550 nm lies between 0.4 and 0.6 
at 37 ºC, shaking constantly at 300 xg. 
5. Bacterial cells were rapidly cooled in ice water, shaking constantly after which they were 
centrifuged in two 125 ml propylene tubes at 3000 xg for 10 minutes at 4 ºC using the 
JA-10 rotor and J2-21 Beckman centrifuge (Beckman Coulter, Inc., Fullerton, CA, USA). 
6. The supernatant was discarded and the pellet resuspended in 125 ml Tfb1. This solution 
was allowed to incubate for 30 minutes on ice after which the bacterial cells were 
centrifuged at 3000 xg for 10 minutes at 4 ºC using the JA-10 rotor and J2-21 Beckman 
centrifuge. 
7. The bacterial cells were gently resuspended in 80 ml Tfb2 after which 300 µl were 
aliquoted into 0.5 ml eppendorf tubes. Freeze in liquid nitrogen or dry ice. These aliquoted 
cells were then stored at -70 ºC for further use. 
Transformation steps 
1. The ligation mix (containing the vector and insert) was added to 100 µl of E. coli 
(Fermentas, U.S.A) MC1061 competent cells. 
2. This was then incubated on ice for 30 min, followed by 5 min incubation at 37 ºC. 
3. The reactions were then immediately placed on ice for 2 min. 
4. Luria broth (900 µl) was added and incubated at 37 ºC for 1 hour. 
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5. 100 μl of each reaction was plated on warmed (0.1mg/ml) ampicillin-containing agar 
plates as well as on agar plates (containing no ampicillin) and incubated at 37 ºC 
overnight. 
6. An image of the plates was captured using a scanner (Bio-Rad gel Doc machine) 
 
3.2.2.8 Colony PCR 
Colony PCR is a technique by which the success of cloning can be evaluated. In this case, 
colony PCR was used to confirm the presence of the insert. 
Ten colonies were picked randomly and mixed with 10 µl of sterile distilled water in each 
tube, making colony mixes. This was then used as a template and the PCR reactions were run 
as per table 3 and table 4, Appendix 3, using specific primers to amplify LASS4 and LASS5 
fragments. 
To check which colonies were carrying the insert, PCR products were ran on a 1.0% agarose 
gel parallel to a 50bp molecular marker in 1X TBE buffer at 80V for 1.5 hr. 
The mixes that contained the insert were each added to 6 ml of LB containing ampicillin to a 
final concentration of 0.1 g/ml and incubated overnight on a 37 ºC shaking incubator. The 
incubator was set at 150 xg. This step was done to ensure that all bacterial cells present in the 
colony mix contained the LASS4 and LASS5 inserts and other contaminating bacteria would 
die due to the inability to express ampicillin resistant gene. This was also to ensure growth 
and multiplication of bacterial cells as well as the recombinant plasmids they contain. 
Sufficient bacterial growth was determined by the medium turning turbid or milky. 
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3.2.2.9 Plasmid extraction 
Plasmid DNA extraction is the method used to extract plasmid DNA from bacterial cells such 
as E coli. The plasmid DNA was purified from the overnight cultures using the WizardPlusTM 
SV Miniprep DNA Purification System kit (Promega). This was done by following the 
manufacturer’s instructions. All steps were carried out at room temperature. 
The first step was to aliquot 0.8 ml (overnight cultures) and 0.2 ml of glycerol into 1.5 ml 
eppendorf tubes. This was mixed by pipetting and stored at -80 ºC as the glycerol stock. The 
second step was to centrifuge the overnight culture for 8 min at 12000 xg at room temperature 
(RT). This was followed by thoroughly resuspending pellet with 250 µl cell resuspension 
solution. A 250 µl cell lysis solution was then added to the suspension, this was inverted 4–5 
times to mix. This was followed by the addition of 10 µl alkaline protease solution, inverted 
4–5 times to mix, and incubated at RT for 5 min. A 350 µl neutralising solution was added to 
the suspension, inverted 4–5 times for mixing. This was followed by centrifuging at 12000 xg 
for 10 min at RT. The spin column was inserted into the collection tube, where the cleared 
lysate was decanted. This was centrifuged at 12000 xg at RT for 1 min, the flow through was 
discarded and the spin column was reinserted back into the collection tube. The plasmid 
DNA was washed through two steps with wash solution (ethanol added), the first step with 
750 µl and the second step with 250 µl, with centrifuging at RT 12000 xg after every wash. 
The spin column was then transferred into a sterile 1.5 ml eppendorf tube and the collection 
tube was discarded. The plasmid DNA was then eluted with 70 µl of nuclease free water and 
this was spun at 12000 xg at RT. The spin column was then discarded and the plasmid DNA 
was stored at -20 ºC for use. 
NB:  PCR was run using LASS4 and LASS5 specific primers to confirm the presence of the 
inserts before sending for sequencing. 
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3.2.2.10 Sequencing and Data analysis 
The purified clone was sent to Inqaba-Biotech Industries (SA) to determine the sequence of 
the LASS4 and LASS fragments. Results were analysed using Finch Server and BLAST at 
URL: http://www.ncbi.nlm.nih.gov. This was done to compare the sequence obtained from 
Inqaba-Biotech, to reference sequences of LASS4 and LASS5, obtained from NCBI. 
3.2.2.11 Real-Time PCR 
Real-Time PCR is a technique that simultaneously quantifies and amplifies a specific part of 
a given DNA molecule. Real-Time PCR is used to determine whether or not a specific 
sequence is present in the sample, and if present, the number of copies present in the sample. 
Quantitative Real-Time PCR (qRT-PCR) is used to quantify the amount of a target gene in a 
sample. QRT-PCR can be divided into absolute (measures total amount of target gene in a 
sample) and relative (compares the amount of target gene between two samples) quantification. 
The main aim of this project was to determine and compare the expression levels of CerS4 
and CerS5 in endometrial and colon cancer, and thus relative qRT- PCR was used. 
The primers were designed in such a way as to avoid forming a hairpin-loop and dimers, as 
these interfere with the accuracy of the results. The primers were then sent to Inqaba-Biotec 
for synthesis. Quantitative Real-Time (qReal-Time) PCR was done using SYBR Green kit 
(Bio-Rad). SYBR green is a fluorescent dye that binds to double stranded PCR product and 
fluoresces. Because multiple SYBR Green molecules bind to a single amplification product, 
SYBR Green is very sensitive. Thus, the amount of fluorescence is equivalent to the amount 
of the product accumulated. cDNA synthesised from the non-cancerous and cancerous, 
treated and untreated cell lines under investigation were used as templates. The gene expression 
curves were analysed and compared between the normal and cancer samples using Amplicon 
software (Bio-Rad). 
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No template was added in the negative control. 
cDNA was synthesised and a series of 5X dilutions were used to construct  standard curves 
for LASS4 (using GMMe), LASS5 (using Caco-2) and β-actin (using HT-29) cDNA, shown 
in table 5a-5c, Appendix 5. The reaction mix was set-up as indicated in table 5d, and table 5e 
shows the Real-Time PCR conditions, Appendix 5. The Livak Method 2-ΔΔCT was used to 
analyse the results. β-actin was previously shown by (Senkal et al., 2007; Jin et al., 2009; 
Schiffmann et al., 2009) as a suitable internal control for CerS4 and CerS5. This method was 
chosen because the amplification efficiencies of target (LASS 4 and/ or LASS 5) and internal 
control (β-actin) are ± 5% apart. 
The Livak method (2-ΔΔCT), (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008) was 
used to calculate the relative expression level of CerS4 and CerS5 in endometrial and colon 
cell lines. The GMMe and Caco-2 cell lines were used as calibrator samples, whereas Hec-1A 
and HT-29 were used as test samples. Furthermore, all untreated cells were use as calibrator 
samples while treated cells were used as test samples. 
3.2.2.12 Statistical analysis 
The results were expressed as means ± standard error means (SEM) for at least three 
independent experiments, using Graphpad Prism 5. Significant differences were determined 
using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test. 
Appendix 4 shows statistical analysis for FACS, while Appendix 5 shows statistical analysis 
for qRT-PCR. A probability level of p <0.05 was considered significant. 
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CHAPTER 4 
RESULTS 
4.1 INTRODUCTION 
This chapter addresses the research questions and objectives discussed in section 1.6 and 
section 1.7, and it is divided into two sections, the bio-informatics analysis section and the 
gene expression analysis section. As CerSes (4 and 5) have been implicated in cancer biology, 
we sought to use bio-informatics to investigate how CerS4 and CerS5 activities can be 
influenced by other proteins. Previous studies show that 70–80% of proteins share at least 
one identical function with their interacting partners (Deng et al., 2003; Letovysky and Kasif, 
2003; Zhang et al., 2009). Protein-protein interaction databases (STRING, InAct and Bio-
GRID) were used to determine possible protein-protein interactions for CerS4 and CerS5. 
Sequence alignment tools (Multi-Align, Clustal omega and COBALT) were then used to 
check for domain conservation and sequence similarities between CerS (4 and 5) sequences 
and their protein interacting partners, as previously reported by Zhang et al., (2009) that 
protein function can be inferred using domain or sequence similarities. QRT-PCR was 
subsequently used to study gene expression levels of CerS4 and CerS5 in endometrial and 
colon cancer. FACS analysis was then used to study and quantify apoptosis. This lead to the 
investigation of the relationship between CerS (4 and 5), and apoptosis, using qRT-PCR, i.e. 
qRT-PCR was done before and after apoptosis induction in treated and untreated samples, 
using the Livak method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). 
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4.2 BIO-INFORMATICS ANALYSIS OF PROTEINS THAT 
POTENTIALLY INTERACT WITH CERS4 AND CERS5 
4.2.1 Identification of proteins that potentially interact with CerS4 and 
CerS5 
In using STRING database, at least 30 proteins were discovered to possibly interact with 
CerS4, shown in figure 4.1. Twelve proteins were discovered to be protein interactors of 
CerS5, presented in figure 4.2. Only predicted interactions were revealed for both CerS4 and 
CerS5. These results indicate that little is known about CerS4 and CerS5 protein structure. 
Furthermore, these results reveal that the CerS4 and CerS5 interacting partners are involved 
in apoptosis, in cell-cycle regulation and in cell proliferation. Interestingly, some of the 
protein interactors are involved in bone and cartilage formation, and also in the central 
nervous system regulation. The results obtained from IntAct and Bio-GRID show that CerS4 
and CerS5 interact with proteins involved in ubiquitination. (Results from these databases, 
IntAct and Bio-GRID are obtained from experimentally determined interactions (Wagner et 
al., 2011; Calderwood et al., 2007). 
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Figure 4.1 - LASS 4 protein interaction network using STRING database:  Single lines only show a 
predicted protein interaction and double lines illustrating a stronger interaction. Triple lines showing 
an interaction between a ligand and its receptor (STRING-Protein-Interaction Network). The double 
lines are only observed between CerS4 interacting partners and not directly between CerS4 and its 
interacting partners. The ligand-receptor interaction is observed between TRH and TRHR. These results 
indicate that little is known about CerS4 protein structure, and implicates these protein interacting 
partners as potential interactors. 
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Figure 4.2 - LASS 5 predicted protein interaction network using STRING database:  Single lines 
only showing a predicted protein interaction. (STRING-Interaction Network). Only predicted interactions 
are observed with CerS5 and there is no strong evidence yet of stronger interactions. 
4.2.2 Implication of CerS4 and CerS5 interacting partners in cell-cycle 
regulation and cellular homeostasis 
Table 4.1 and 4.2 summarises the interactions seen in STRING diagrams for LASS4 and 
LASS5. The information for each protein was obtained from STRING database and NCBI. 
Accession numbers were also obtained from NCBI. In addition, at least five protein-interacting 
partners were shown to be shared by CerS4 and CerS5, accession numbers highlighted in red 
in both table 4.1 and table 4.2. 
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Table 4.1:  CerS4 predicted protein interacting partners 
Protein name and  
Accession number Function/Information 
• SPHK1 
Sphingosine kinase 1 
 NP_892010.2 
Catalyses the phosphorylation of sphingosine to form 
sphingosine 1-phosphate (SPP), a lipid mediator with both 
intra- and extracellular functions. Also acts on D-erythro-
sphingosine and to a lesser extent sphinganine, but not other 
lipids, such as D,L-threo-dihydrosphingosine, N,N-
dimethylsphingosine, diacylglycerol, ceramide, or 
phosphatidylinositol 
• SPHK2 
Sphingosine kinase 2 
 NP_064511.2 
Catalyses the phosphorylation of sphingosine to form 
sphingosine 1-phosphate (SPP), a lipid mediator with both 
intra- and extracellular functions. Also acts on D-erythro- 
dihydrosphingosine, D-erythro-sphingosine and L-threo- 
dihydrosphingosine 
• CERK 
Ceramide kinase 
 NP_073603.2 
Catalyses specifically the phosphorylation of ceramide to form 
ceramide 1-phosphate. Acts efficiently on natural and analog 
ceramides (C6, C8, C16 ceramides, and C8-dihydroceramide), 
to a lesser extent on C2-ceramide and C6-dihydroceramide, but 
not on other lipids, such as various sphingosines 
• ATP10D 
ATPase, class V, type 10D 
 AAI31536.1 
ATPase, class V, type 10D 
• UGT8 
UDP glycosyltransferase 8 
 AAC51187.1 
Catalyses the transfer of galactose to ceramide, a key 
enzymatic step in the biosynthesis of galactocerebrosides, 
which are abundant sphingolipids of the myelin membrane of 
the central nervous system and peripheral nervous system 
• FADS3 
Fatty acid desaturase 3 
 NP_068373.1 
Fatty acid desaturase 3 
• BMP2 
Bone morphogenetic protein 2 
 NP_001191.1 
Induces cartilage and bone formation 
• BMP6 
Bone morphogenetic protein 2 
 NP_001709.1 
Induces cartilage and bone formation 
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Protein name and  
Accession number Function/Information 
• SPTLC3 
Serine palmitoyltransferase, 
long chain base subunit 3 
 NP_060797.2 
Serine palmitoyltransferase (SPT). The heterodimer formed 
with LCB1/SPTLC1 constitutes the catalytic core. The 
composition of the serine palmitoyltransferase (SPT) complex 
determines the substrate preference. The SPTLC1-SPTLC3-
SSSPTA isozyme uses both C14-CoA and C16-CoA as 
substrates, while the SPTLC1-SPTLC3-SSSPTB has the ability 
to use a broader range of acyl-CoAs without apparent preference 
• CDK14 
Cyclin-dependent kinase 14 
 NP_036527.1 
May play a role in meiosis as well as in neuron differentiation 
• TRHR 
Thyrotropin-releasing 
hormone receptor 
 NP_003292.1 
Receptor for thyrotropin-releasing hormone. This receptor is 
mediated by G proteins which activate a phosphatidylinositol-
calcium second messenger system 
• MRPS27 
Mitochondrial ribosomal 
protein S27 
 NP_055899.2 
Mitochondrial ribosomal protein S27 
• PGK 
Phosphoglycerate kinase 1 
 NP_000282.1 
In addition to its role as a glycolytic enzyme, it seems that 
PGK-1 acts as a polymerase alpha cofactor protein (primer 
recognition protein) 
• ST8STA1 
ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 1 
 NP_003025.1 
Involved in the production of gangliosides GD3 and GT3 from 
GM3; gangliosides are a subfamily of complex 
glycosphinglolipds that contain one or more residues of sialic 
acid 
• TM2D1 
TM2 domain containing 1 
 EAX06599.1 
May participate to beta-amyloid-induced apoptosis via its 
interaction with beta-APP42 
• INHA 
Inhibin alpha 
 NP_002182.1 
Inhibins and activins inhibit and activate, respectively, the 
secretion of follitropin by the pituitary gland. Inhibins/activins 
are involved in regulating a number of diverse functions such 
as hypothalamic and pituitary hormone secretion, gonadal 
hormone secretion, germ cell development and maturation, 
erythroid differentiation, insulin secretion, nerve cell survival, 
embryonic axial development or bone growth, depending on 
their subunit composition. Inhibins appear to oppose the 
functions of activins. 
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Protein name and  
Accession number Function/Information 
• INSIG1 
Insulin induced gene 1 
 NP_005533.2 
Mediates feedback control of cholesterol synthesis by 
controlling SCAP and HMGCR. Functions by blocking the 
processing of sterol regulatory element-binding proteins 
(SREBPs). Capable of retaining the SCAP-SREBF2 complex 
in the ER thus preventing it from escorting SREBPs to the 
Golgi. Seems to regulate the ubiquitin-mediated proteasomal 
degradation of HMGCR. May play a role in growth and 
differentiation of tissues involved in metabolic control. May 
play a regulatory role during G0/G1 transition of cell growth 
• FOSL1 
FOS-like antigen 1 
 BAD96622.1 
FOS-like antigen 1 
• TRH 
Thyrotropin-releasing 
Hormone 
 NP_009048.1 
Functions as a regulator of the biosynthesis of TSH in the 
anterior pituitary gland and as a neurotransmitter/ 
neuromodulator in the central and peripheral nervous systems 
• TFPT 
TCF3 (E2A) fusion partner (in 
childhood Leukemia) 
 NP_037474.1 
TCF3 (E2A) fusion partner (in childhood Leukemia) 
• CLN8 
Ceroid-lipofuscinosis, 
neuronal 8 
 NP_061764.2 
Could play a role in cell proliferation during neuronal 
differentiation and in protection against cell death 
• CCND2 
Cyclin D2 
 NP_001750.1 
Essential for the control of the cell cycle at the G1/S (start) 
transition 
• TDH 
L-threonine dehydrogenase 
 CAC82738.1 
L-threonine dehydrogenase 
• SPP2 
Secreted phosphoprotein 2 
 AAI06706.1 
Could coordinate an aspect of bone turnover 
• SPINT2 
Serine peptidase inhibitor, 
Kunitz type, 2 
 AAH12868.1 
Serine peptidase inhibitor, Kunitz type, 2 
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Protein name and  
Accession number Function/Information 
• FAM195A 
Family with sequence 
similarity 195, member A 
 NP_612427.2 
Family with sequence similarity 195, member A 
• SIVA1 
Apoptosis-inducing factor 
 NP_006418.2 
Induces CD27-mediated apoptosis. Inhibits BCL2L1 isoform 
Bcl-x(L) anti-apoptotic activity. Inhibits activation of NF-
kappa- B and promotes T-cell receptor-mediated apoptosis 
• CCL4L1 
Chemokine (C-C motif) ligand 
4-like 1 
 AAI44395.1 
Monokine with inflammatory and chemokinetic properties. 
Binds to CCR5. One of the major HIV-suppressive factors 
produced by CD8+ T-cells. Recombinant MIP-1-beta induces a 
dose-dependent inhibition of different strains of HIV-1, HIV-2, 
and simian immunodeficiency virus (SIV). The processed form 
MIP-1-beta (3-69) retains the abilities to induce down-
modulation of surface expression of the chemokine receptor 
CCR5 and to inhibit the CCR5- mediated entry of HIV-1 in T-
cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 
isoform B 
• SGPP1 
Sphingosine-1-phosphate 
phosphatase 1 
 AAK26660.1 
Has enzymatic activity against both sphingosine 1 phosphate 
(S1P) and dihydro-S1P. Regulates intracellular and extracellular 
S1P levels 
• ASAH1 
Acid ceramidase 1 
 NP_004306.3 
Hydrolyses the sphingolipid ceramide into sphingosine and 
free fatty acid 
• BPLF1 
Large tegument protein 
(Epstein Barr Virus) 
 CAD53402 
Involved in deubiquitination activity. 
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Table 4.2:  CerS5 predicted protein interacting partners 
Protein name Function/Information 
• SMPD2 
Sphingomyelin 
phosphodiesterase 2, neutral 
membrane (neutral 
sphingomyelinase) 
 NP_003071.2 
Converts sphingomyelin to ceramide. Hydrolyse 1-acyl-2- 
lyso-sn-glycero-3-phosphocholine (lyso-PC) and 1-O-alkyl-2-
lyso- sn-glycero-3-phosphocholine 
• GAL3ST1 
Galactose-3-O-
sulfotransferase 1 
 NP_004852.1 
Catalyses the sulfation of membrane glycolipids. Seems to 
prefer beta-glycosides at the non-reducing termini of sugar 
chains attached to a lipid moiety. Catalyses the synthesis of 
galactosylceramide sulfate (sulfatide), a major lipid component 
of the myelin sheath and of monogalactosylalkylacylglycerol 
sulfate (seminolipid), present in spermatocytes (By similarity). 
Also acts on lactosylceramide, galactosyl 1-alkyl-2-sn-glycerol 
and galactosyl diacylglycerol (in vitro)  
• GTF2IRD1 
General transcription factor II-
Irepeat domain containing 1 
 NP_057412.1 
May be a transcription regulator involved in cell-cycle 
progression and skeletal muscle differentiation. May repress 
GTF2I transcriptional functions, by preventing its nuclear 
residency, or by inhibiting its transcriptional activation. May 
contribute to slow-twitch fiber type specificity during myogenesis 
and in regenerating muscles. Binds troponin I slow-muscle fiber 
enhancer (USE B1). Binds specifically and with high affinity to 
the EFG sequences derived from the early enhancer of HOXC8 
• ANKS1B 
Ankyrin repeat and sterile 
alpha motif domain containing 
1B 
 NP_690001.3 
Isoform 2 may participate in the regulation of nucleoplasmic 
coilin protein interactions in neuronal and transformed cells 
• SPHK1 
Sphingosine kinase 1 
 NP_892010.2 
Catalyses the phosphorylation of sphingosine to form 
sphingosine 1-phosphate (SPP), a lipid mediator with both intra- 
and extracellular functions. Also acts on D-erythro-sphingosine 
and to a lesser extent sphinganine, but not other lipids, such as 
D,L-threo-dihydrosphingosine, N,N-dimethylsphingosine, 
diacylglycerol, ceramide, or phosphatidylinositol  
• SPHK2 
Sphingosine kinase 2 
 NP_064511.2 
Catalyses the phosphorylation of sphingosine to form 
sphingosine 1-phosphate (SPP), a lipid mediator with both 
intra- and extracellular functions. Also acts on D-erythro- 
dihydrosphingosine, D-erythro-sphingosine and L-threo- 
dihydrosphingosine 
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Protein name Function/Information 
• CLN8 
Ceroid-lipofuscinosis, 
neuronal 8 
 NP_061764.2 
Could play a role in cell proliferation during neuronal 
differentiation and in protection against cell death 
• ELOVL6 
ELOVL family member 6, 
elongation of long chain fatty 
acids 
 NP_076995.1 
Fatty acid elongase specific to C12-C16 saturated and 
monoinsaturated fatty acids  
• TFPT 
TCF3 (E2A) fusion partner (in 
childhood Leukemia) 
 NP_037474.1 
TCF3 (E2A) fusion partner (in childhood Leukemia) 
• TP53INP2 
Tumour protein p53 inducible 
nuclear protein 2 
 NP_067025.1 
Tumour protein p53 inducible nuclear protein 2 
• SNCB 
Synuclein, beta 
 NP_003076.1 
Non-amyloid component of senile plaques found in Alzheimer 
disease. Could act as a regulator of SNCA aggregation process. 
Protects neurons from staurosporine and 6-hydroxy dopamine 
(6OHDA)-stimulated caspase activation in a TP53/p53-dependent 
manner. Contributes to restore the SNCA anti-apoptotic function 
abolished by 6OHDA. Not found in the Lewy bodies associated 
with Parkinson disease 
• CCL4L1 
Chemokine (C-C motif) ligand 
4-like 1 
 AAI44395.1 
Monokine with inflammatory and chemokinetic properties. Binds 
to CCR5. One of the major HIV-suppressive factors produced 
by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-
dependent inhibition of different strains of HIV-1, HIV-2, and 
simian immunodeficiency virus (SIV). The processed form 
MIP-1-beta(3-69) retains the abilities to induce down-modulation 
of surface expression of the chemokine receptor CCR5 and to 
inhibit the CCR5- mediated entry of HIV-1 in T-cells. MIP-1-
beta(3-69) is also a ligand for CCR1 and CCR2 isoform B 
• UBC 
Polyubiquitin 
 NP_066289 
This gene represents a ubiquitin gene, ubiquitin C. The encoded 
protein is a polyubiquitin precursor. Conjugation of ubiquitin 
monomers or polymers can lead to various effects within a cell, 
depending on the residues to which ubiquitin is conjugated. 
Ubiquitination has been associated with protein degradation, 
DNA repair, cell cycle regulation, kinase modification, 
endocytosis, and regulation of other cell signaling pathways. 
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Following the protein interactions and determining their functions, CerS4 and CerS5 amino-
acid sequences were aligned with the sequences of their predicted-interacting partners to 
examine sequence similarity. 
4.2.3 Determination of sequence similarity between CerS4 and CerS5 and 
their interacting partners 
The sequence alignment tools (Multi-Align, Clustal Omega and COBALT) reveal that there is 
no domain or sequence similarity shared between CerS4, CerS5 and their potential interacting 
partners, when all aligned together. Little sequence similarity is observed when CerS (4 and 
or 5) is aligned with one of its interacting partners, Appendix 3, figure 3a to figure 3f. Figure 
4.3 shows CerS4 amino acid sequence alignment with five of its interacting partners and 
figure 4.4 shows CerS5 amino acid sequence alignment with five of its interacting partners 
using Multi-Align tool. As bio-informatics revealed a possible protein-interaction between 
CerS4 or CerS5 and proteins involved in apoptosis, gene expression studies were implemented 
to determine the expression level of CerS4 and CerS5 in cancerous versus non-cancerous 
samples, which also included apoptosis induction and FACS analysis. 
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Figure 4.3 - The CerS4 and its protein interacting partners using Multi-Align:  These results show 
an alignment between CerS4 and five of its potential protein interacting partners (also shown to share 
these protein interacting partners with (CerS5)). Low consensus sequence is shown in blue. 
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Figure 4.4 - The CerS5 and its protein interacting partners using Multi-Align:  These results 
show an alignment between CerS5 and five of its potential protein interacting partners (also shown to 
share these protein interacting partners with (CerS4)). Low consensus sequence is shown in blue. 
Protein-protein interactions are important in cellular functions such as signal transduction and 
apoptosis (Pawson and Nash, 2003). Using STRING database, only predicted interactions 
were revealed for both CerS4 and CerS5. However, using BioGRID database, polyubiquitin 
(UBC) was found to interact with CerS5 (This study was conducted and proven by Wagner et 
al., 2011). Furthermore, using IntAct database, CerS4 was shown to interact with the BFLP1 
protein of the EBV virus through virus-human protein interactions, a mechanism used by this 
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virus to replicate and persist in the body (This study was determined and proven by 
Calderwood et al., 2007). Figure 3g and 3h (Appendix 3) show sequence alignment of CerS4 
and CerS5 from IntAct and BioGRID databases, using MultiAlign. Additionally, little is known 
about the fundamental structure of the human CerS4 and CerS5 (LASS monomer, homodimer, 
heterodimer and higher order structure with additional accessory proteins), (Teufel et al., 
2009), and this remains the same to date. However, results shown by the STRING interaction 
protein network implicate a role of CerS4 and CerS5 in cell-cycle regulation and apoptosis. 
Interestingly, our findings indicate that CerS4 and CerS5 share no sequence similarity with 
their protein interacting partners. It was also revealed in this study that there was no potential 
protein interaction between the LASS proteins, as they share high sequence similarity. These 
findings may implicate distinct biological roles of CerSes, as previously demonstrated by 
Senkal et al., (2010). As previously shown that proteins interacting together share at least one 
identical function (Zhang et al., 2009), our Bio-informatics results revealed that CerS4 and 
CerS5 interact with proteins involved in apoptosis and cell cycle regulation. 
4.3 GENE EXPRESSION ANALYSIS OF CERS4 AND CERS5 IN 
COLON AND ENDOMETRIAL CANCERS 
Following the Bio-informatics analysis, gene expression analysis was done to determine the 
expression level of CerS4 and CerS5 in colon and endometrial cancers. Total RNA was 
extracted from all cell lines, and then was subjected to reverse transcription for cDNA 
synthesis, which was used as a template for qRT-PCR. The expression levels of CerS4, CerS5 
were determined in malignant (test) compared to their non-malignant (calibrator) samples. 
Flow cytometry (FCM)/ fluorescence-activated cell sorter (FACS) was then used to analyse 
apoptosis. QRT-PCR was repeated to compare CerS4, CerS5 expression levels in treated and 
untreated samples. 
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4.3.1 Induction of apoptosis by 5FU and anastrozole 
Both endometrium and colon cell lines were cultured and apoptosis was induced. FACS was 
used to determine and analyse apoptosis induced by 5 µM of 5-FU in colon cell lines and 2 µM 
of anastrozole in endometrial cell lines. For each experiment/cell-line, blank (Untreated and 
Unstained), and a negative control (Untreated and Stained with annexin-V and/or propidium 
iodide (PI)), were used. The blank was used to localise the population of a particular cell-line. 
The negative control was used to determine the true apoptotic signal from the false background/ 
necrosis. Results are represented in cytograms and bar graphs. The vertical and the horizontal 
gates were consistent for each experiment and its controls. 
4.3.2 Apoptosis analysis using Flow cytometry (FCM)/ fluorescence-
activated cell sorting (FACS) analysis 
Experiments were done on three independent occasions, each in triplicate. Figue 4.5 , 4.6 
(GMMe) and figure 4.7, 4.8 (Hec-1A) show FACS analysis and graphs resulting from 
statistical analysis for endometrial cell lines. 
 
Figure 4.5 - FACS analysis of GMMe endometrial cell-line:  A represents the blank (untreated cells), 
B represents the negative control (untreated but stained) and C represents the 24h treated cells, stained 
with annexin-V and PI. This demonstrates the exposure of phophatidylserine from the cytosolic side 
to the surface in the endometrium cells (GMMe), treated with 2 µM of anastrozole for 24h. Annexin-
V FITC apoptosis detection assay results are represented in histograms, denoting the percentage of 
cells staining positive for annexin-V in the M1 region.  
0.53% 4.04% 14.3% 
A B C 
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FACS analysis for GMMe cells
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Figure 4.6 - ANOVA and Tukey’s multiple comparison test for GMMe endometrial cells:  The 2 
µM anastrozole treated cells (GMMe experiment) show a higher apoptosis percentage rate compared 
to the untreated cells. Statistical differences were determined with one-way ANOVA followed by the 
Tukey’s post comparison test. P <0.05 was considered significant.  
 
Figure 4.7 - FACS analysis of Hec-1A cell-line:  A represents the blank (untreated cells), B represents 
the negative control (untreated but stained) and C represents the 24h treated cells, stained with 
annexin-V and PI. This represents the exposure of phophatidylserine from the cytosol to the surface in 
the endometrium cells (Hec-1A), treated with 2 µM of anastrozole for 24h. Annexin-V FITC 
apoptosis detection assay results are represented in histograms, denoting the percentage of cells 
staining positive for annexin-V in the M1 region. 
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Figure 4.8 - ANOVA and Tukey’s multiple comparison test for Hec-1A cells treated with 2 µM 
anastrozole:  The Hec-1A treated (experiment) cells exhibit almost a three -fold of apoptosis percentage 
rate compared to the negative control. Statistical differences were determined with one-way ANOVA 
followed by the Tukey’s post comparison test. P <0.05 was considered significant. 
Results for FACS and statistical analysis in colon cells are shown below. Figure 4.9, 4.10 
(Caco-2) and figure 4.11, 4.12 (HT-29) illustrate analysed results for FACS and statistics in 
colon cell lines respectively. The FACS values for ALL cell lines and their statistical analysis 
are shown in Appendix 4. Table 4a–4d show FACS and statistical analysis for endometrial 
cell lines, while table 4e–4h show FACS and statistical analysis for colon cell lines. 
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Figure 4.9 - FACS analysis of Caco-2 cells treated with 5 µM of 5FU:  A represents the blank 
(untreated cells), B represents the negative control (untreated but stained), C represents the 24h treated 
cells and D represents the 48h treated cells, stained with annexin-V and PI. The histograms show the 
exposure of phophatidylserine from the cytosolic side to the surface in the colon cells (Caco-2), treated 
with 5 µM of 5-FU for 24h and 48h. Annexin-V FITC apoptosis detection assay results are 
represented in histograms, denoting the percentage of cells staining positively for annexin-V in the 
M1 region. 
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FACS analysis for Caco-2 cells
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Figure 4.10 - ANOVA and Tukey’s multiple comparison test for Caco-2 cells:  The Caco-2 24h 
and 48h treatment show an elevated apoptosis percentage rate compared to the two controls. Using the 
one-way ANOVA test and the Tukey’s multiple post comparison test, p <0.05 was considered 
significant. 
 
Figure 4.11 - FACS analysis of HT-29 colon cells treated with 5 µM of 5FU:  A represents the 
blank (untreated cells), B represents the negative control (untreated but stained), C represents the 24h 
0.47% 0.98% 
4.66% 5.70% 
A B 
C D 
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treated cells and D represents the 48h treated cells, stained with annexin-V and PI. The results 
demonstrate the exposure of phophatidylserine from the cytosolic side to the surface in the colon cells 
(HT-29), treated with 5 µM of 5-FU for 24h and 48h. Annexin-V FITC apoptosis detection assay 
results are represented in histograms, denoting the percentage of cells staining positive for annexin-V 
in the M1 region. 
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Figure 4.12 - ANOVA and Tukey’s multiple comparison test of HT-29 cells:  Both of the treated 
groups illustrate an increased apoptosis percentage rate. 5 µM of 5FU was more effective after 48h 
with more apoptotic cells compared to 24h. Using the on-way ANOVA test and the Tukey’s multiple 
post comparison test, p <0.05 was considered significant. 
Following FACS analysis, the same cell culture and apoptosis induction conditions were 
followed. Total RNA was extracted from all cell lines when confluence was reached. RNA 
was then subjected to reverse transcription polymerase reaction. 
4.3.3 Polymerase Chain Reaction (PCR) and Insert Confirmation 
PCR was carried out to verify the correct insert size and this was then followed by sequencing 
to verify correct target sequence. PCR was done for both LASS 4 and LASS 5 genes. A 
 
69 | P a g e  
temperature gradient was first run for each primer set and the optimum annealing temperature 
was determined for each primer set. For more accurate results, it has been suggested that Real-
Time PCR primers yield products of 50bp to 250bp. The annealing temperature for LASS 4 
was 53°C and 55°C for LASS5. The PCR products were analysed by gel electrophoresis 
using a parallel molecular weight marker, and resulted in a single band for specificity. The 
PCR products were then cloned into a pGEM-T Easy vector and sent for sequencing, for 
insert confirmation. The results were then aligned with reference sequences on NCBI. LASS4 
matched 100% and LASS 5 matched 99%. Figure 4.13 and 4.14 show the PCR product and 
sequence alignment for LASS4. Figure 4.15 and 4.16 show the PCR product and sequence 
alignment for LASS5. 
 
Figure 4.13 - LASS 4 PCR products:  The LASS 4 inserts show a size of 175bp run parallel to a 
50bp molecular weight marker. Lane 1 is a marker, lane 3 to 5 being LASS4 175bp PCR products. 
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Score = 324 bits (175), Expect = 2e-92 
Identities = 175/175 (100%), Gaps = 0/175 (0%) 
Strand=Plus/Plus 
 
Query  1171  TCCTCTACACCACATACTACGAGTCCATCAGCAACAGGGGCCCCTTCTTCGGCTACTACT 
1230 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  83    TCCTCTACACCACATACTACGAGTCCATCAGCAACAGGGGCCCCTTCTTCGGCTACTACT 
142 
 
Query  1231  TCTTCAACGGGCTTCTGATGTTGCTGCAGCTGCTGCACGTGTTCTGGTCTTGCCTCATTC 
1290 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  143   TCTTCAACGGGCTTCTGATGTTGCTGCAGCTGCTGCACGTGTTCTGGTCTTGCCTCATTC 
202 
 
Query  1291  TGCGCATGCTCTATAGCTTCATGAAGAAGGGCCAGATGGAGAAGGACATTCGTAG 
1345 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  203   TGCGCATGCTCTATAGCTTCATGAAGAAGGGCCAGATGGAGAAGGACATTCGTAG 
257  
Figure 4.14 - LASS 4 cloned product in reference to the NCBI sequence (NM_024552.1):  The 
results show 100% sequence alignment. 
 
Figure 4.15 - LASS 5 PCR products:  The LASS 5 inserts illustrate a size of 124bp, the PCR products 
were run parallel to a 50bp marker. Lane 1, a 50bp molecular weight marker, lane 3 to 6 being 124 
LASS 5 PCR product.  
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Score = 224 bits (121), Expect = 1e-62 
Identities = 123/124 (99%), Gaps = 0/124 (0%) 
Strand=Plus/Plus 
 
Query  401  TCGGAGGAATCAGGACAAGCCCCCAACGCTTACTAAATTCTGTGAAAGCATGTGGAGATT 
460 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  40   TCGGAGGAATCAGGACAAGCCCCCAACGCTTACTAAATTCTGTGAAAGCATGTGGAGATT 
99 
 
Query  461  CACATTTTATTTATGTATATTCTGCTATGGAATTAGATTTCTCTGGTCGTCACCTTGGTT 
520 
            |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  100  CACATTTTGTTTATGTATATTCTGCTATGGAATTAGATTTCTCTGGTCGTCACCTTGGTT 
159 
 
Query  521  CTGG  524 
            |||| 
Sbjct  160  CTGG  163  
Figure 4.16 - LASS 5 cloned product in reference to the NCBI sequence (NM_147190.1):  The 
sequence alignment results show 99% identity between the two sequences.  
4.3.4 Gene expression using Real-Time polymerase Chain Reaction 
Following conventional PCR (which was used to optimise and amplify the target sequences 
of CerS4 and CerS5), Real-Time PCR (which has been proven to be more sensitive than the 
conventional method of amplification (Sanguinetti et al., 2003) was used for quantification 
purposes. 
4.3.5 Quantitative Real-time Polymerase Reaction (QRT-PCR) 
The optimised primers for LASS4 and LASS5 (designed using the Bio-Rad Beacon software) 
through conventional PCR, were then used for qRT-PCR. The primers were run at a temperature 
gradient (50°C to 60°C) for LASS4, LASS5 and β-actin. The optimum temperatures were 
determined from the melting curves and they were as follows: 55°C for LASS4 and 53°C for 
LASS5 and 54°C for β-actin. Single peaks for melting curves showed the specificity of each 
primer set. Standard curves were then constructed using known cDNA concentration. Results 
were analysed using quantitation curves from the Bio-Rad Mini-Opticon version 3. 
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4.3.6 The Melting Curves 
The single peaks in the melting curves denote primer specificity. The melting curve for LASS4 
is shown in figure 4.17, and the melting curves for LASS5 and β-actin are demonstrated in 
Appendix 5, figure 5a and figure 5d. 
 
Figure 4.17 - The LASS4 melting curves with a melting temperature of 83°C:  The single peak 
shows product specificity. (---) represents a negative control where no template was added, but both 
primers were added to the reaction mixture. 
Following the correct amplification of the targets, standard curves were constructed to 
determine the efficiency of the primers. 
4.3.7 Primer Efficiency Assessment using standard curves 
Unlike conventional PCR primers, real-time PCR primer efficiency has to be assessed using 
standard curves. The efficiency is expressed in a percentage and the standard efficiency range 
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is between 90% and 100%. The standard curves of the genes under investigation were 
constructed using serial dilutions (5X) from the original cDNA, template. The CT-values were 
obtained from the quantitation curves and the log concentration of each dilution was determined. 
The standard curves were then plotted, i.e, the log concentration versus the CT-values, and the 
slope was determined from the curve. Furthermore, the percentage efficiency (%E) for each 
primer set was determined using the standard curve and the following formula was used: 
 %E = (10(-1/slope)-1) X 100 
NB:  For perfect amplification, % E >90 and r2 should be -3 
4.3.8 Standard Curves 
The following standard curves were constructed using MS-Excel, and the slope was directly 
calculated from the graphs. The CT-values were obtained from the quantitation curves. 
Figure 4.18 shows the quantitation curves and figure 4.19 shows the STD curve constructed 
for LASS 4. Table 4.3 shows the log concentrations of the cDNA and the CT-values, which 
were used to draw-up the standard curve for LASS4. The quantitation curves and STD curves 
for LASS 5 and β-actin are shown in Appendix 5, figure 5b, 5c and table 5f for LASS 5 and 
figure 5e, 5f and table 5g for β-actin, Appendix 5. 
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Figure 4.18 - Amplification curves for LASS4:  The CT values with the corresponding 
concentrations were used to construct the STD curve. 
 
Figure 4.19 - Standard curve for LASS4:  The slope was calculated to be -3.6 and the r2 value is 
0.9785. Table 4.3 shows the Log concentrations from the start concentration of 168.5ng/µl of the 
cDNA from the GMMe cell line, using a 5X dilution. 
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The percentage efficiency for LASS 4, LASS 5 and β-actin were calculated and were all 
between 90% and 100%. Calculations are shown in Appendix 4. 
Table 4.3:  Shows the log concentrations with the corresponding threshold cycle for LASS4 
Log Concentration Threshold Cycle 
2.22 23.2 
1.53 25.05 
0.8 28.38 
 
4.3.9 Relative Quantification RT-PCR of LASS4 and LASS5 expression 
normalised against an endogenous control (reference gene) 
Relative quantification or comparative quantification measures the relative change in mRNA 
expression levels. It determines the changes in steady state mRNA levels of a gene across 
multiple samples and expresses it relative to the levels of another RNA, in this study 
cancerous samples (colon and endometrial) were compared to non-cancerous samples. The 
expression level for each gene was determined and calculated as an expression ratio. This 
was calculated using the Livak method (2-∆∆CT). 
NB: ∆CT =  CT (Test target-Test ref) 
 ∆CT =  CT (Calibrator target-Calibrator ref) 
  =  2-[ΔCT (test) – ΔCT (calibrator)] 
The expression level of a target gene in the calibrator is assumed to remain constant, hence 
equals to 1 (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). The fold ratio above 
one was considered and an up-regulation of a target gene in the test sample, and a ratio value 
below one was considered a down-regulation, hence it was calculated as -1/fold ratio below 
one (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). 
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4.3.10 QRT-PCR analysis 
Each experiment (non-cancerous and cancerous, treated and untreated), was done three times 
independently in triplicate. Results were expressed as means ± standard error means (SEM). 
To examine the relationship between LASS4 and/or LASS5 and apoptosis, using apoptosis 
inducing drugs, LASS4 and LASS5 mRNA expression levels were compared in endometrial 
and colon cells before and after apoptosis treatment. The Livak method was still used to 
compare the expression levels of LASS4 and LASS5 in treated and untreated cells, normalised 
to β-actin. Figure 4.20 shows LASS4 in endometrial cell lines normalised to β-actin. 
LASS4 mRNA expression level analysis 
  
Figure 4.20 - Amplification curves for LASS 4 (with β-actin) in endometrial cell lines GMMe and 
Hec-1A:  The average ΔCT values for the three independent experiments were, 21.32 in GMMe and 
18.89 in Hec-1A cells. β-actin average ΔCT values for the three independent experiments in GMMe 
and Hec-1A cells were 16.46 and 16.09 respectively. 
NB:  The CT values for the three independent experiments are shown in Appendix 5, table 5h and 
figure 4.20 is a representative diagram of the three experiments. 
---β-actin (GMMe) 
---β-actin (Hec-1A) 
---LASS4 (GMMe) 
---LASS4 (Hec-1A) 
---Negative Control 
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The equation described above, section 4.3.9 was used and results are expressed as means ± 
SEM. Appendix 5 shows Table 5h for LASS4 CT values in endometrial cell lines before 
apoptosis treatment. The CT-values for LASS4 in GMMe and Hec-1A after apoptosis induction 
are shown in table 5i and 5j. Table 5k-5o shows the CT-value readings for LASS4 in colon 
cell lines before and after apoptosis treatment. 
NB:  Different annealing temperatures were used for each primer set (i.e for β-Actin and 
LASS 4), as running a temperature gradient using a Mini-Opticon Version 3 (Bio-Rad) was 
possible. Below are the statistically analysed (ANOVA and Tukey’s multiple comparison 
test) results for LASS4 and LASS5 in fold change expressed as means ± standard error mean 
(SEM) for at least three independent experiments. Figure 4.21 and 4.22 show statistically 
analysed results for LASS4 in endometrial cell lines. 
                  LASS4 relative expression level in endometrial cell-lines
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Figure 4.21 - Graph showing LASS4 relative expression level in Hec-1A cells compared to GMMe 
prior to apoptosis treatment:  The expression level of LASS4 in endometrial cancerous cell-line is 
~4-fold up-regulated compared to the non-cancerous counterpart (GMMe). 
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          LASS4 relative expression level in GMMe cell-line
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LASS4 relative expression level in Hec-1A cells
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Figure 4.22 - Graphs showing the relative expression level of LASS4 in endometrial cells before 
and after apoptosis treatment:  The induction of apoptosis in both GMMe (left) and Hec-1A (right) 
cells resulted in the down regulation of LASS4 in both cell lines, more especially in Hec-1A cells, 4.5 
fold, and 2.7 fold in GMMe. 
Figure 4.23 to 4.25 graphs show results expressed as mean ± SEM for LASS4 in colon cell 
lines, for at least three independent experiments. 
LASS4 relative expression level in colon cell-lines
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Figure 4.23 - Graph showing LASS4 relative expression level in HT-29 compared to Caco-2 cells 
before apoptosis induction:  LASS4 is shown to be ~10 fold up-regulated in the highly malignant 
HT-29 cells compared to Caco-2 colon cells.  
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LASS4 relative expression level in Caco-2 24h treated cells
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LASS4 relative expression level in Caco-2 48h treated cells
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Figure 4.24 - Graphs showing the expression level of LASS4 in Caco-2 colon cells after 24h and 
48h apoptosis induction:  LASS4 expression level was observed to be down-regulated after 24h (left) 
and 48h (right). There was no significant difference between 24h (2 fold) and 48h (2.9 fold) treatment. 
LASS4 relative expression level in HT-29 24h treated cells
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LASS4 relative expression level in HT-29 48h treated cells
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Figure 4.25 – Graphs showing LASS4 relative expression level in HT-29 cells after 24h and 48h 
induction of apoptosis:  A decline in LASS4 mRNA expression level was shown after 24h, 1.25 fold 
(left) and significantly after 48h, 3.7 fold (right) of the treatment for apoptosis. The down regulation 
of LASS4 mRNA level was almost 3X after 48h, compared to 24h. 
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LASS5 mRNA expression level analysis 
Appendix 5, Table 5p shows the CT-values of LASS5 with β-actin in GMMe and Hec-1A 
cells before apoptosis induction. The readings for GMMe and Hec-1A CT-values after 
apoptosis induction are shown in Appendix 5, table 5q and table 5r of LASS5. The LASS5 
CT-values in colon cells before and after apoptosis treatment are seen in Appendix 5, table 
5S-5w. Figure 4.26 and 4.27 show the relative expression level of LASS5 in endometrial cell 
lines, expressed as means ± SEM for at least three independent experiments. 
LASS5 relative expression level in endometrial cells
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Figure 4.26 - Graph illustrating LASS5 relative expression level in Hec-1A cells compared to 
GMMe cells:  An up-regulation of ~50 fold of LASS5 mRNA expression level is demonstrated in 
endometrial cancer (Hec-1A) relative to its non-cancerous counterpart. 
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LASS5 relative expression level in GMMe cells
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LASS5 relative expression level in Hec-1A cells
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Figure 4.27 - Graphs illustrating the relative expression level of LASS5 in endometrial cell lines 
after apoptosis induction:  A down-regulation of LASS5 mRNA was observed in GMMe, 7 .14 fold 
(left) and Hec-1A, 14.29 fold (right) after inducing apoptosis. The reduction in LASS5 mRNA in 
Hec-1A cells doubles, compared to GMMe. 
The expression level of LASS5 in colon cell lines was also determined. Figure 4.28 showing 
amplification curves is a representation of all three independent experiments of LASS5 in 
colon cell lines normalised to β-actin. 
  
Figure 4.28 - Amplification curves for LASS 5 (with β-actin) in colon cell lines Caco-2 and HT-29:  
The average CT values for the three independent experiments for Caco-2 were 25.29 and 20.19 for 
---β-actin HT-29 
---β-actin Caco-2 
---LASS5 (HT-29) 
---LASS5 (Caco-2) 
---Negative control 
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HT-29. β-actin amplification curves are also illustrated in this figure with average CT values of 16.46 
for Caco-2 and 16.09 for HT-29, calculated from three independent experiments. 
Figure 4.29 to 4.31 graphs show the relative expression levels of LASS5 in colon cell lines 
expressed as means ± SEM for at least three independent experiments. 
LASS5 relative expression level in colon cell-lines
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Figure 4.29 - Graph illustrating the relative expression level of LASS5 in HT-29 and Caco-2 
colon cell lines before apoptosis treatment:  LASS5 mRNA expression level was shown to be ~25-
fold up-regulated in colon cancer. 
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LASS5 relative expression level in Caco-2 48h treated cells
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Figure 4.30 - Graphs illustrating LASS5 mRNA relative expression level in Caco-2 cells treated 
for apoptosis:  A more significant decline in LASS5 mRNA is seen after 48h, 7.7 fold (right) 
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compared to 24h, 1.5 fold (left) apoptosis treatment. A 5X decline in LASS5 mRNA is seen after 48h 
compared to 24h apoptosis induction. 
   
LASS5 relative expression level in HT-29 24h treated cells
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LASS5 relative expression level in HT-29 48h treated cells
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Figure 4.31 - Graphs illustrating the relative expression level of LASS5 in HT-29 cells after 
apoptosis induction:  LASS5 was shown to be more significantly down-regulated in HT-29 cells, 
with 17.86 fold down-regulation after 24h (left) 58.82 fold down-regulation after 48h (right) induction 
of apoptosis. After 48h, the decline in LASS5 mRNA level was three-fold, compared to 24h 
treatment. 
4.3.11 Statistical analysis for CerS4 and CerS5 in endometrial and colon 
cancers 
Statistical analysis for LASS4 in endometrial cells is shown in Appendix 5, table 5i–5iii, and 
table 5iv–5vii, show statistical analysis of LASS4 in colon cells. Appendix 5, table 5viii–5x 
shows statistical analysis for LASS5 in endometrial cells while table 5xi–5xv shows LASS5 
statistical analysis in colon cancer cells. 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
5.1 GENERAL DISCUSSION 
Understanding the regulation of CerSes is important since this family of genes has not just 
been implicated in cancer development, but in cancer progression and targeted in cancer therapy 
(Teufel et al., 2009). Currently, the main function of LASS genes is to produce ceramide 
(Mizutani et al., 2005; Huang et al., 2011). However, it is still possible that LASS proteins 
containing the Hox domain may have an additional novel function in addition to the ceramide 
synthase activity, in which the entire domain plays a critical role, as the Hox domain containing 
proteins have been shown to be transcription regulators (Gehring et al., 1994). In contrast, it 
was previously shown by Mesika et al., (2007) that the first 15 amino acids of the Hox domain 
which contain the key residue (N51) involved in DNA binding are missing in CerSes. Mesika 
et al., (2007) further demonstrated that CerS5 and CerS6 contain a conserved region of 12 
amino acids at the C-terminus of the Hox domain, which is essential for their catalytic activity. 
Previously it was shown that the TLC domain only is critical for CerSes function (Ogretment, 
2006), now part of the Hox-domain plays a vital role in the activity of CerS5 and CerS6 
(Mesika et al., 2007). These findings could implicate distinct biological roles for the CerSes 
isoforms, as the shorter isoform completely lacks the Hox-domain and part of the TLC domain, 
while the longer isoform retains the two domains. CerSes are emerging as potential candidates 
to further examine how orthologs, homologs and isoforms of the same gene can influence 
cellular homeostasis. 
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5.2 BIO-INFORMATICS ANALYSIS FOR LASS 4 AND LASS 5 
It has been previously shown that proteins that share high sequence similarity may be involved 
in similar biological functions (Zhang et al., 2009). Surprisingly, even though CerSes share a 
high sequence similarity, none of these protein-family members were revealed to interact 
together. This also supports reports that although CerSes share high sequence similarity, they 
may be involved in distinct biological functions (Levy and Futerman, 2010). Little is known 
about CerS4 and CerS5 and the protein-protein interactions identified in this study were 
identified using STRING database (showing experimentally determined and predicted 
interactions), BioGRID and IntAct databases, which show experimentally determined 
interactions. Furthermore, these results also show the interaction of CerS4 and CerS5 with 
proteins involved in apoptosis (SIVA1 and TMD2), cell-cycle regulation (CCND2 and 
CDk14) and cell proliferation (CLN8). Interestingly, CerS4 and CerS5 have also been shown 
to interact with proteins involved in bone and cartilage formation, and the central nervous 
system regulation. Furthermore, using BioGRID and IntAct databases, CerS5 was shown to 
interact with polyubiquitin, while CerS4 was revealed to interact with BFLP1 protein of the 
EBV virus, also implicated in ubiquitination (Calderwood et al., 2007; Whitehurst et al., 
2009; Wagner et al., 2011). These results indicate that CerS4 and CerS5 may be involved in 
other essential cellular processes apart from apoptosis. Surprisingly, when CerS4 and/ or 
CerS5 were aligned with all of their potential interacting partners, no consensus sequence was 
revealed. 
In summary, these results show that CerS4 and CerS5 are involved in apoptosis and also are 
very likely to be involved in other unelucidated cellular functions. However, it is not surprising 
to obtain predicted protein interactions for both CerS4 and CerS5, as little is known about 
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their fundamental structure (monomers, homodimers, heterodimers and higher order structures) 
(Teufel et al., 2009). 
5.3 GENE EXPRESSION ANALYSIS 
The bio-informatics analysis carried out here suggest a role for CerS4 and CerS5 in cancer 
biology, especially in apoptosis, as indicated in literature (Ogretmen, 2006; Schiffmann et al., 
2009; Huang et al., 2011). Thus the relationship between CerS4, CerS5 and apoptosis was 
examined. This was further studied at a gene expression level where the possible relationship 
between CerS4 and or CerS5 and apoptosis inducing drugs, (5-FU in colon cells and 
anastrozole in endometrial cells) was investigated. 
5.3.1 Induction of apoptosis by 5-FU and anastrozole in colon and 
endometrial cells 
5-FU and anastrozole were both used at optimally defined doses as described in previous work 
(Thant et al., 2008; Matsumoto et al., 2008). The apoptosis percentage rate was calculated 
from all cells staining positive for Annexin-V and PI negative (i.e in quadrant 2). An 
apoptosis percentage rate of more than 24.6% was observed in the human endometrial 
cancerous cell line (Hec-1A), compared to the non-cancerous counterpart (GMMe), with an 
apoptosis percentage rate of 14.3% after 24h. In colon cells, a 5.7% apoptosis percentage rate 
was seen in HT-29 cells compared to 4.37% apoptosis percentage rate in Caco-2 cells after 48 
h. The analysed results were shown to be statistically significant with P <0.05. However, 
there was no significant difference between 24 h and 48 h apoptosis treatment in the Caco-2 
colon cell-line. This could be that these cells (Caco-2) reached an apoptotic threshold at 24h 
and could not be sensitised to 5FU beyond 24 h. An increase in dosage of 5FU instead of 
time or an increase in both parameters of dosage and time could probably have yielded a 
higher apoptosis percentage rate in Caco-2 cells. Furthermore, it has been previously reported 
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that Caco-2 cells are more resistant to 5FU mediated apoptosis (Carnesecchi et al., 2002). 
Generally, the effectiveness of 5FU in colon cancer has been shown to be increased by other 
molecules such as geraniol and selenium (Carnesecchi et al., 2002; Thant et al., 2008). Both 
endometrial and colon cancer cell lines showed an increased apoptosis percentage rate, when 
compared to their non-malignant (differentiated) counterparts. The effect of 5-FU and 
anastrozole on the expression levels of CerS4 and CerS5 was then determined using 
quantitative real time-PCR. 
5.3.2 The effect of 5-FU and anastrozole on the mRNA expression level of 
CerS4 and CerS5 in endometrial and colon cancer 
Following the treatment of colon and endometrium cells with apoptosis inducing factors, 
sequence analysis showed that the designed primers were specific to the target sequences of 
LASS 4 and LASS 5. The single peaks in the melting curves demonstrate primer specificity. 
Subsequent to the correct sequence confirmation, both CerS4 and CerS5 were shown to be up-
regulated in the cancers of colon and endometrium. The comparison was done between the 
cancerous cell line and the non-cancerous (differentiated) cell line, before and after apoptosis 
treatment. The up-regulation of CerS4 in endometrial cancer was seen before apoptosis 
treatment, and a down-regulation of CerS4 was observed after apoptosis treatment in 
endometrial cells, especially in Hec-1A cells. Furthermore, CerS4 was also found to be up-
regulated in colon cancer, prior to apoptosis induction and a down-regulation of CerS4 was 
demonstrated after treatment for apoptosis in colon cell lines. A more significant decline (3.7 
fold) was observed in HT-29 cells after 48h apoptosis treatment. CerS5 was also shown to be 
up-regulated in both endometrial and colon cancers prior to apoptosis induction, and was also 
demonstrated to decline following apoptosis treatment in endometrial and colon cancers. 
Both CerS4 and CerS5 showed a higher degree of down-regulation in the cancerous cell lines 
compared to the non-cancerous (differentiated) counterparts. This was observed in both colon 
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and endometrial cells, for both CerS4 and CerS5. These findings suggest a role of CerS4 and 
CerS5 in the apoptotic regulation of cancers of the colon and endometrial. Furthermore, CerS4 
and CerS5 may be involved in similar biological functions (in colon and endometrial cancers), 
as they are predicted here to share some of the protein-interacting partners. 
The LASS family of genes has been previously implicated in cancer biology (Ogretmen, 
2006). Disruption in the synthesis of ceramide by these genes may result in disruption of 
apoptosis regulation (Schiffmann et al., 2009). The goal of this research was to determine the 
relationship between CerS4, CerS5 and apoptosis, in colon and endometrial cancers, 
especially since failure to properly regulate apoptosis (i.e. resistance to apoptosis) is one of 
the hallmarks of cancer (Hanahan and Weinberg, 2011). Findings in this study indicated a 
possible role of CerS4, CerS5 in the apoptotic regulation of colon and endometrial cancers. 
Schiffmann et al., (2009) also demonstrated a relationship between CerSes, that is, CerS2, 
CerS4, CerS5 and CerS6 (2, 4-6) and apoptosis in breast cancer. Their results showed 
elevated CerSes (2, 4-6) levels in breast cancer, which served as anti-apoptotic molecules by 
protecting cells from undergoing apoptosis. Furthermore, it was also shown by Karahatay et 
al., (2007) that it is not all of LASS members that have tumour protective effects. LASS1 was 
shown to have anti-tumour effects in head and neck squamous cell carcinoma, by inhibiting 
the activation of telomerase, which has tumour promotion. In contrast, CerS5 and CerS6 have 
been shown to activate telomerase, leading to tumour promoting properties in the breast 
tissue (Schiffmann et al., 2009). The reports implicating elevated rates of ceramide de novo 
synthesis in many tumours are growing, considering the anti-tumour properties of this SL. 
This was also demonstrated by Knapp et al., (2010), reporting high levels of CerSes in 
endometrial cancer, compared to normal endometrium, and their possible explanation for this 
double-edged SL was that activation of this pathway is required to fulfil the increased 
demand of proliferating cancer cells for building blocks of complex SLs such as SM and 
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glycosphingolipids, which are important constituents of biological membranes. However, it 
still remains a challenge for many studies to demonstrate which CerSes precisely play a role 
in the tumourigenesis of different types of cancer, as indicated by Senkal et al., (2007) that 
different CerSes can play opposing roles in the same tissue. From this investigation, it was 
apparent that CerS4 and CerS5 are involved in the apoptosis regulation of the endometrial and 
colon cells. This was apparent because induction of apoptosis in endometrial and colon cells 
resulted in the down-regulation of CerS4 and CerS5 in endometrial and colon cancer. However, 
a definite conclusive line cannot be drawn at this point, whether both these genes are pro or 
anti-apoptotic, or exerting opposing roles in the pathogenesis of colon and endometrial cancers. 
5.4 CONCLUSION 
To further understand the mechanisms of these genes in cancer biology, more future work 
still needs to be done. This may include the over-expression of CerS4 or CerS5 in colon and 
endometrial cells. This would help to determine if CerS4 or CerS5 protects the cells from 
undergoing apoptosis, or inhibit excessive cell growth. In addition, investigating whether the 
inhibition of CerS4 and CerS5 in colon and endometrial cells by si-RNA or compounds known 
to inhibit the synthesis of ceramide by CerSes (such as fumonisin) may lead to apoptosis or 
cell survival, may help better understand the biological roles of each of these CerSes. In-vitro 
protein assays will also aid in determining and confirming interacting partners for CerS4 and 
CerS5. Furthermore, determining the up-stream and down-stream targets of CerS4 and CerS5 
will contribute significantly towards uncovering how exactly CerS4 and CerS5 influence the 
fate of a cell. Ceramide deregulation has not just been implicated in cancer development, but 
also in cancer progression and cancer therapy (Teufel et al., 2009). Therefore, targeting this 
family of genes and understanding their precise roles in cancer and apoptosis is a promising 
therapeutic tool for the discovery of new anti-cancer drugs or improving the existing ones. 
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APPENDICES 
APPENDIX 1 
10X PBS 
Reagents (for 1 L): 
• NaCl – 80 g 
• KCl – 2.0g 
• Na2HPO4:7H2O – 14.4 g 
• KH2PO4 - 2.4 g 
• Pure Water H2O – 1 L 
Procedure: 
1. Add each of reagents to 800 ml of pure water. 
2. Adjust by adding enough pure water to make 1000 ml of solution. 
3. Adjust pH between 7.2 and 7.6 
4. Autoclave and Store at room temperature 
1X PBS (1L) 
100 ml of 10X PBS and 900 ml of water 
10X TE 
• 100 ml 1 M Tris-HCl pH 7.5 
• 20 ml 500 mM EDTA pH 8.0 
• 880 ml pure water 
1X TE (100 ml) 
10 ml 10X TE and 90 ml pure water 
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10X TBE 
Reagents (for 1L): 
• 108 g of Tris base [tris(hydroxymethyl)aminomethane] 
• 55 g of boric acid 
• 7.5 g of EDTA, disodium salt 
• deionised water 
Procedure: 
1. Dissolve the Tris, boric acid and EDTA in 800 ml of pure water. 
2. Dilute the buffer to 1 L. Undissolved white clumps may be made to dissolve by placing 
the bottle of solution in a hot water bath, and store at room temperature. 
1X TBE 
100 ml of 10X TBE and 900 ml of pure water 
Calculations of concentrations for apoptosis inducing drugs: 
1. C = concentration 
2. N = moles 
3. M = mass 
4. V = volume 
MM = molecular mass 
5 Flourouracil (5FU): 
50 mg of 5FU was dissolved in 1 ml PBS = 50 mg/ml 
5 µM 5FU = 0.065 mg in 100 ml 
5 µM = 5 µmol/L 
Molecular mass (MM) 5FU = 130.08 g/mol 
C = n/V 
N = CV 
    = 5 µmol/L X 0.1 L 
   = 0.5 µmol 
N = m/MM 
M = nMM 
   = 0.5 µmol X 130.08 g/mol 
   = 0.065 mg 
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Anastrozole: 
40 mg dissolved in 1 ml DMSO (Sigma-Aldrich, USA) = 40 mg/ml 
2 µM anastrozole = 0.0587mg in 100 ml 
2 µM = 2 µmol/L 
Molecular mass (MM) anastrozole = 293.4 g/mol 
C = n/V 
N = CV 
   = 2 µmol/L X 0.1 L 
   = 0.2 µmol 
N = m/MM 
M = nMM 
   = 0.2 µmol X 293.4 g/mol 
   = 0.0587 mg 
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APPENDIX 2 
Table 2a:  Shows the Reverse transcription composition 
Reagents Volume (µl) 
iScript-Buffer 4 
RNA 2 
Reverse transcriptase 1 
Nuclease-Free H2O 13 
Total volume 20 
 
Table 2b:  cDNA synthesis cycling conditions 
Temperature (ºC) Time (min) 
25 5 
42 30 
85 5 
 
Table 2c:  Shows the composition of Polymerase Chain Reaction (PCR) Reaction 
Reagents Experiment Negative Control 
2X PCR Master Mix (Promega,USA) 10 10 
Forward Primer 1 1 
Reverse Primer 1 1 
Nuclease Free H2O 6 8 
Template (cDNA) 2 0 
Total volume 20 20 
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Table 2d:  Shows the PCR Conditions used to amplify the region of interest 
Step Temperature (ºC) Time (min) 
Initial Denaturation 95 2 
Denaturation 94 0.5 
Annealing x 1 
Extension 72 1 
Final extension 72 10 
Hold 4 ∞ 
x represents the annealing temperature of either LASS4 or LASS5 which was 53 ºC for 
LASS4, 55 ºC for LASS5 and 54 ºC for β-actin. 
NB:  35 cycles were run and the results were analysed by agarose gel electrophoresis 
 
Figure 2a – A diagrammatic representation of p-GEM-T-Easy cloning vector:  The PCR insert is 
ligated into the multiple cloning site, between 49 and 64 (www.promega.com). 
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Table 2e:  Shows the ligation system using the p-GEM-T-easy vector 
Reagents 
Experimental 
Samples (µl) 
Negative control 
(µl) 
2X Ligation Buffer 5 5 
p-GEM-T-easy vector (10ng/µl) 1 1 
T4 ligase 1 1 
PCR product 2 - 
sd H2O 1 3 
Total 20 20 
sdH2O = sterile distilled water 
Tfb solutions 
Tfb1 
30 mM KAc (Fluka Chemie Gmbh, Sigma-Aldrich Chemie 
GmbH, Steinheim, Switzerland) 
50 mM MnCl2 (Riedel-de-Haën, Sigma-Aldrich 
Laborchemikalien GmbH, Seelze) 
100 mM KCl (Riedel-de-Haën, Sigma-Aldrich 
Laborchemikalien GmbH, Seelze) 
10 mM Calcium Chloride (CaCl2) (Riedel-de-Haën, Sigma- 
Aldrich Laborchemikalien GmbH, Seelze) 
15% (v/v) Glycerol 
Solution was sterilised by filtration 
  
 
110 | P a g e  
Tfb2 10 mM MOPS, pH7.0 
109 
75 mM CaCl2 
10 mM KCl 
15% (v/v) Glycerol 
Solution was sterilised by filtration 
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APPENDIX 3 
 
Figure 3a – The sequence alignment between CerS4 and EBV-BFLP1 protein using MultiAlign 
database:  This interaction was determined using the IntAct protein-protein interaction database and 
the EBV-BFLP1 sequence was obtained from NCBI. Red residues show high consensus while blue 
residues show low consensus. 
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Figure 3b – The sequence alignment between CerS4 and SPHK1 using Clustal Omega:  No 
consensus sequence was revealed, especially when CerS4 sequence was aligned with all of its protein 
interacting partners. 
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Figure 3c – The sequence alignment between CerS4 and SPHK1 using COBALT:  Sequence 
similarity between the two sequences is shown in red, whereas non-identical amino acids are shown in 
blue. 
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Figure 3d – The sequence alignment between CerS5 and polyubiquitin-C (UBC) using 
MultiAlign database:  This protein interaction was obtained from BioGRID and the UBC amino acid 
sequence was obtained from NCBI. The high consensus is shown in red and the low consensus is 
shown in blue. 
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Figure 3e – The sequence alignment between CerS5 and SPHK2 using Clustal Omega:  No 
consensus sequence was revealed, especially when CerS5 sequence was aligned with all of its protein 
interacting partners. 
 
116 | P a g e  
 
Figure 3f – The sequence alignment between CerS5 and SPHK2 using COBALT:  Sequence 
similarity between the two sequences is shown in red, whereas non-identical amino acids are shown in 
blue. 
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APPENDIX 4 
Flow Cytometry/FACS analysis 
Endometrial cell lines 
 
Figure 4a – The cytograms illustrating the endometrial GMMe cell line undergoing apoptosis:   
(a) The viable cell population (blank), (b) The negative control and (c) The experiment-apoptosis 
induced. The gates of the controls and the experiment are the same. A 15% apoptosis was seen. 
 
Figure 4b – The cytograms illustrating the endometrial Hec-1A cell line undergoing apoptosis:  
(a) The viable cell population (blank), (b) The negative control and (c) The experiment- apoptosis 
induced. The experiment’s apoptosis signal was subtracted from the positive control, to get the true 
apoptosis signal, and a 33% apoptosis signal was seen. The experiments were done in triplicate for 
each cell-line.  
  
A B C 
A B C 
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Colon cell lines 
 
Figure 4c – Diagrammatic representations (cytograms) of the Caco-2 cell line undergoing 
apoptosis:  (a) Showing the viable population (blank), (b) the negative control, (c) 24 hrs-treatment 
and (d) 48 hrs treatment. The horizontal and the vertical gates of the controls is the same as the 
experiments. A 6% apoptosis signal was seen in Caco-2 cells after 24 hrs, and 7.8% after 48 hrs. 
A B 
C D 
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Figure 4d – The Flow cytometric representation of the HT-29 cell line undergoing apoptosis:  
The viable cell population (blank), (b) the negative control, (c) the 24 hrs treatment and (d) the 48 hrs 
treatment. A 11% for 24 hrs and 14% for 48 hrs apoptosis signal was observed.  
Tables 4a and 4b show the FACS analysis for GMMe cell-line and Hec-1A and table 4c and 
4d show the statistical analysis of GMMe and Hec-1A. Table 4e and 4f show the FACS 
analysis for Caco-2 and HT-29, while table 4g and 4h show the statistical analysis for Caco-2 
and HT-29 colon cell lines. 
NB: Values in the experiment column denote those in the apoptosis quadrant (2), staining 
Annexin V positive and PI negative.    
  
A B 
C D 
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Table 4a:  FACS analysis of GMMe endometrial cell-line 
GMMe Blank Negative Control GMMe experiment 
 0.24 4.26 14.77 
 0.72 3.86 13.97 
 0.63 4.01 14.15 
 
Table 4b:  FACS analysis for Hec-1A endometrial cell-line 
Hec-1A Blank Negative Control Hec-1A experiment 
 2.36 5.86 25.51 
 1.98 4.98 24.59 
 2.02 5.32 23.68 
 
Table 4c:  GMMe cell line statistical analysis 
Table Analysed Data 1     
One-way analysis 
of variance      
P value P <0.0001     
P value summary ***     
Are means signif. 
different? (P <0.05) Yes     
Number of groups 3     
F 1633     
R squared 0.9982     
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ANOVA Table SS df MS   
Treatment (between 
columns) 307.0 2 153.5   
Residual (within 
columns) 0.5641 6 0.09402   
Total 307.6 8    
Tukey's Multiple 
Comparison Test 
Mean Diff. q 
Significant? 
P <0.05? 
Summary 
95% CI  
of diff 
Blank vs Negative 
control -3.513 19.85 Yes *** 
-4.281 to  
-2.745 
Blank vs GMMe 
experiment -13.77 77.76 Yes *** 
-14.53 to  
-13.00 
Negative control vs 
GMMe experiment -10.25 57.92 Yes *** 
-11.02 to  
-9.485 
 
Table 4d:  Hec-1A cell line statistical analysis 
Table Analysed Data 1     
One-way analysis 
of variance      
P value P <0.0001     
P value summary ***      
Are means signif. 
different? (P <0.05) Yes      
Number of groups 3      
F 1231      
R squared 0.9976      
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ANOVA Table SS df MS   
Treatment (between 
columns) 884.6 2 442.3   
Residual (within 
columns) 2.156 6 0.3593   
Total 886.8 8    
Tukey's Multiple 
Comparison Test 
Mean Diff. q 
Significant? 
P <0.05? 
Summary 
95% CI  
of diff 
Blank vs Negative 
control -3.267 9.440 Yes ** 
-4.768 to  
-1.765 
Blank vs Hec-1A 
Experiment -22.47 64.94 Yes *** 
-23.97 to  
-20.97 
Negative control vs 
Hec-1A Experiment -19.21 55.50 Yes *** 
-20.71 to  
-17.71 
 
Table 4e:  FACS analysis for the Caco-2 colon cell-line 
Caco-2 Blank 
Negative 
Control 
24-hr 48-hr 
 0.32 1.39 4.09 3.63 
 0.25 1.93 4.92 4.52 
 0.46 1.61 5.01 4.97 
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Table 4f:  FACS analysis for the HT-29 colon cell-line 
HT-29 Blank 
Negative 
Control 
24-hr 48-hr 
 0.63 1.24 4.05 60.2 
 0.35 0.92 5.06 5.95 
 0.42 0.78 4.86 5.14 
 
Table 4g:  Caco-2 cell line statistical analysis 
Table Analysed Data 1     
One-way analysis 
of variance      
P value P <0.0001     
P value summary ***     
Are means signif. 
different? (P <0.05) Yes     
Number of groups 4     
F 66.14     
R squared 0.9612     
ANOVA Table SS df MS   
Treatment 
(between columns) 40.05 3 13.35   
Residual (within 
columns) 1.615 8 0.2019   
Total 41.67 11    
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Tukey's Multiple 
Comparison Test 
Mean Diff. q 
Significant? 
P <0.05? 
Summary 
95% CI  
of diff 
Blank vs Negative 
control -1.300 5.012 Yes * 
-2.475 to  
-0.1252 
Blank vs Caco-2 
24h treatment -4.330 16.69 Yes *** 
-5.505 to  
-3.155 
Blank vs Caco-2 
48h treatment -4.030 15.54 Yes *** 
-5.205 to  
-2.855 
Negative control vs 
Caco-2 24h 
treatment -3.030 11.68 Yes *** 
-4.205 to  
-1.855 
Negative control vs 
Caco-2 48h 
treatment -2.730 10.52 Yes *** 
-3.905 to  
-1.555 
Caco-2 24h 
treatment vs Caco-
2 48h treatment 0.3000 1.157 No ns 
-0.8748 to 
1.475 
 
Table 4h:  HT-29 cell line statistical analysis 
Table Analysed Data 1     
One-way analysis 
of variance      
P value P <0.0001     
P value summary ***     
Are means signif. 
different? (P <0.05) Yes     
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Number of groups 4     
F 136.5     
R squared 0.9808     
ANOVA Table SS df MS   
Treatment 
(between columns) 61.62 3 20.54   
Residual (within 
columns) 1.204 8 0.1505   
Total 62.83 11    
Tukey's Multiple 
Comparison Test 
Mean Diff. q 
Significant? 
P <0.05? 
Summary 
95% CI  
of diff 
Blank vs Negative 
control -0.5133 2.292 No ns 
-1.528 to 
0.5012 
Blank vs HT-29 
24h treatment -4.190 18.71 Yes *** 
-5.204 to  
-3.176 
Blank vs HT-29 
48h treatment -5.237 23.38 Yes *** 
-6.251 to  
-4.222 
Negative control vs 
HT-29 24h 
treatment -3.677 16.41 Yes *** 
-4.691 to  
-2.662 
Negative control vs 
HT-29 48h 
treatment -4.723 21.09 Yes *** 
-5.738 to  
-3.709 
HT-29 24h 
treatment vs HT-29 
48h treatment -1.047 4.673 Yes * 
-2.061 to  
-0.03218 
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APPENDIX 5 
Real-Time PCR 
Table 5a:  Shows a 5X dilution series of HT-29 for constructing the STD-curve 
Dilution HT-29 (ng/µl) 
Undiluted 245 
1:5 49 
1:25 9.8 
1:125 1.96 
1:625 0.39 
NB:  Different dilutions were run in duplicates, each cell line was diluted. 
Table 5b:  Shows a 5X dilution series of Caco-2 for constructing the STD-curve 
Dilution Caco-2 (ng/µl) 
Undiluted 131.9 
1:5 26.38 
1:25 5.28 
1:125 1.06 
1:625 0.21 
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Table 5c:  Shows a 5X dilution series of GMMe for constructing the STD-curve 
Dilution GMMe (ng/µl) 
Undiluted 168.5 
1:5 33.7 
1:25 6.74 
1:125 1.35 
1:625 0.27 
 
Table 5d:  Shows the qRT-PCR protocol for LASS4, LASS5 and β-actin 
Reagents Exp (µl) Neg. control (µl) 
SYBR Green 10 10 
Fw primer 0.5 0.5 
Rv primer 0.5 0.5 
Nuclease Free H2O 7 9 
cDNA 2 – 
Total 20 20 
The cancer cell-line was compared to a normal cell line, with the initial concentration of both 
cell lines being the same. 
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Table 5e:  Shows the qRT-PCR incubation using the Mini-Opticon (Bio-Rad) 
Step (Incubation ºC) Time (min) 
95 2 
94 0.5 
x* 0.5 
72 1 
Plate Read – 
Go to line 2, 39 times – 
72 10 
Melting Curve from x to y, 1 °C 0.17 
x* depends on the annealing temperatures, i.e. LASS4 is 53 ºC  and LASS5 is 55 ºC and 
54 ºC for β-actin. 
Results were analysed using the Opticon-Monitor, Bio-Rad, Version 3.1 
 
Figure 5a – LASS5 melting curve with a melting temperature of 84°C:  The single peak illustrates 
the specificity of primers, yielding one product. There was no product amplified in the negative 
control (---) as there was no template added. 
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Figure 5b – Amplification curves for LASS5, for standard curve construction of LASS5:  The 
5X dilution was used to construct a standard curve from the 131.9 ng/µl of Caco-2 cell line 
synthesised cDNA. 
Table 5f:  Shows the log concentrations with the corresponding threshold cycle for LASS5 
Log Concentration Threshold Cycle 
2.12 20.62 
1.42 23.31 
0.7 25.80 
NB:  For β-actin, the HT-29 cDNA synthesised from RNA was used, the concentration was 
245ng/µl 
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Figure 5c – Standard curve for LASS5:  The slope was calculated to be -3.39 and r2 value is 
0.9906. 
 
Figure 5d – β-actin melting-curve with melting temperature of 89 °C:  The primers are shown to 
be specific, yielding only one product. The negative control (---) yielded no product as there was no 
template added to the reaction mixture. 
R2 = 0.9906
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Figure 5e – Amplification curves for β-actin used for standard curve construction:  The CT 
values of these amplification curves together with the log-concentrations, (from initial 245ng/µl HT-
29 cDNA) were used to construct a standard curve. 
Table 5g:  Shows the Log Concentrations of the corresponding threshold cycles for β-actin 
Log Concentration Threshold Cycle 
2.39 13.89 
1.69 16.72 
0.99 18.82 
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Figure 5f – Standard curve for β-actin:  It was constructed using the 5X dilution of HT-29 cDNA. 
Slope = -3.5 and r2 = 0.9927 
The percentage efficiency were calculated as follows; for LASS4, LASS5 and β-actin: 
LASS4 
Slope = -3.6 
     E = 10(-1/slope) 
        = 1.9 
% Efficiency = (E – 1) X 100% 
                    = 90% 
LASS5 
Slope = -3.39 
      E = 10(-1/slope) 
         = 1.97 
% Efficiency = (E -1) X 100% 
                    = 97% 
R2 = 0.9927
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β-actin 
Slope = -3.5 
      E = 10(-1/slope) 
         = 1.93 
% Efficiency = (E -1) X 100% 
                    = 93% 
Each experiment was done in triplicate and the readings for LASS 4 and LASS 5 are 
represented in tables below: 
Tables for LASS4 
Table 5h:  LASS 4 mRNA expression levels in endometrial cell lines before apoptosis treatment 
LASS 4 (2-ΔΔCT) GMMe β-actin Hec-1A β-actin 
6.73 21.93 16.59 18.96 16.37 
3.36 21.04 16.06 19.12 15.89 
3.2 20.98 16.74 18.58 16.02 
 
Table 5i:  LASS 4 mRNA expression level in GMMe apoptosis treatments 
LASS 4 (2-ΔΔCT) GMMe  24h β-actin 24h GMMe 0h β-actin 0h 
0.37 26.63 16.47 24.49 15.76 
0.4 26.14 16.31 24.08 15.58 
0.35 26.21 16.01 24.77 16.10 
 
  
 
134 | P a g e  
Table 5j:  LASS 4 mRNA expression level in Hec-1A apoptosis treatments 
LASS 4 (2-ΔΔCT) Hec-1A 24h β-actin 24h Hec-1A  0h β-actin 0h 
0.24 25.98 16.19 23.32 15.6 
0.27 25.46 16.39 22.86 15.69 
0.16 25.17 15.98 22.25 16.18 
 
Colon cell lines 
Table 5k:  LASS 4 mRNA in colon cell lines Caco-2 and HT-29 before apoptosis treatment 
LASS 4 (2-ΔΔCT) Caco-2 β-actin HT-29 β-actin 
10.63 25.27 16.74 21.41 16.29 
10.78 25.03 16.13 20.96 15.49 
4.69 24.46 16.41 21.72 15.9 
 
Table 5l:  LASS 4 mRNA expression level in Caco-2 24h apoptosis treatments  
LASS4 (2-ΔΔCT) Caco-2 24h β-actin 24h Caco-2 0h β-actin 0h 
0.56 27.82 16.7 26.43 16.15 
0.28 27.13 16.41 25.12 16.26 
0.66 26.93 16.23 25.81 15.72 
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Table 5m:  LASS 4 mRNA expression level in Caco-2 48h apoptosis treatments 
LASS4 (2-ΔΔCT) Caco-2  48h β-actin 48h Caco-2   0h β-actin 0h 
0.23 26.6 16.17 24.73 16.39 
0.51 25.83 16.72 24.33 16.19 
0.28 26.08 16.56 24.14 16.48 
 
Table 5n:  LASS 4 mRNA expression level in HT-29 24h apoptosis treatments 
LASS 4 (2-ΔΔCT) HT-29 24h β-actin 24h HT-29 0h β-actin 0h 
0.45 23.33 16.53 21.99 16.35 
1.65 22.62 16.72 22.5 15.88 
0.30 22.91 16.11 21.73 16.66 
 
Table 5o:  LASS 4 mRNA expression levels in HT-29 48h apoptosis treatment 
LASS 4 (2-ΔΔCT) HT-29 48h β-actin 48h HT-29 0h β-actin 0h 
0.19 22.16 16.32 19.67 16.2 
0.10 23.01 16.12 19.28 15.77 
0.51 22.57 16.35 20.56 15.31 
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Tables for LASS 5 
Endometrial cell lines 
Table 5p:  LASS 5 mRNA expression level in endometrial cell lines GMMe and Hec-1A  
LASS5 (2-ΔΔCT) GMMe β-actin Hec-1A β-actin 
38.05 26.48 16.41 20.71 15.89 
51.98 26.12 16.34 19.79 16.16 
39.67 25.82 15.65 21.02 15.71 
 
Table 5q:  LASS 5 mRNA expression level in GMMe apoptosis treatments  
LASS5 (2-ΔΔCT) GMMe 24h β-actin 24h GMMe 0h β-actin 0h 
0.13 26.03 16.48 22.89 16.27 
0.14 25.26 15.97 22.2 15.75 
0.16 25.75 16.14 22.57 15.58 
 
Table 5r:  LASS 5 mRNA expression level in Hec-1A apoptosis treatments  
LASS5 (2-ΔΔCT) Hec-1A 24h β-actin 24 Hec-1A 0h β-actin 0h 
0.08 24.89 16.31 20.83 15.81 
0.05 24.38 16.04 20.15 16.09 
0.08 25.07 16.61 20.52 15.76 
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Colon cell lines 
Table 5s:  LASS 5 mRNA expression level in colon cell lines Caco-2 and HT-29 before apoptosis 
treatment 
LASS5 (2-ΔΔCT) Caco-2 β-actin HT-29 β-actin 
33.82 25.77 16.14 20.62 16.07 
21.11 25.16 16.5 19.81 15.55 
20.68 24.96 16.73 20.15 16.29 
 
Table 5t:  LASS 5 mRNA expression level in Caco-2 24h apoptosis treatment  
LASS5 (2-ΔΔCT) Caco-2 24h β-actin 24h Caco-2 0h β-actin 0h 
0.57 24.93 16.07 24.09 16.03 
0.37 25.22 16.56 23.64 16.43 
1.05 24.61 16.77 24.41 16.18 
 
Table 5u:  LASS 5 mRNA expression level in Caco-2 48h apoptosis treatment  
LASS5 (2-ΔΔCT) Caco-2 48h β-actin 48h Caco-2 0h β-actin 0h 
0.22 24.26 16.48 21.82 16.23 
0.11 24.37 15.84 21.15 15.8 
0.07 24.85 16 21.53 16.55 
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Table 5v:  LASS5 mRNA expression level in HT-29 24h apoptosis treatments  
LASS5 (2-ΔΔCT) HT-29 24h β-actin 24h HT-29 0h β-actin 0h 
0.04 24.78 15.62 19.84 15.44 
0.06 24.41 16.05 20.39 16.11 
0.07 23.94 15.91 20.61 16.32 
 
Table 5w:  LASS 5 mRNA expression level in HT-29 48h apoptosis treatment  
LASS5 (2-ΔΔCT) HT-29 48h β-actin 48h HT-29 0h β-actin 0h 
0.03 24.18 16.31 18.08 15.46 
0.01 24.52 16.15 17.96 16.03 
0.01 24.8 15.93 18.36 15.99 
 
Statistical Analysis using the ANOVA test 
LASS4 endometrial cell lines 
Table 5i:  Statistical analysis using ANOVA test for LASS4 endometrial cells 
Table Analysed Data 1 
Column A GMMe 
vs vs 
Column B Hec-1A 
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Unpaired t test 
P value 0.0409 
P value summary * 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 2.976, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N = 3 
Mean ± SEM of column B 4.430 ± 1.151 N = 3 
Difference between means -3.430 ± 1.152 
95% confidence interval -6.629 to -0.2310 
R squared 0.6889 
F test to compare variances 
F, DFn, Dfd 397.4, 2, 2 
P value 0.0050 
P value summary ** 
Are variances significantly different? Yes 
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Table 5ii:  Statistical analysis using ANOVA test for LASS4 in GMMe  24h apoptosis treated 
cells 
Table Analysed Data 1 
Column A L4 GMMe 0h 
vs vs 
Column B L4 GMMe 24h 
Unpaired t test 
P value 0.0005 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 10.53, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.3733 ± 0.01453 N=3 
Difference between means 0.6267 ± 0.05954 
95% confidence interval 0.4614 to 0.7919 
R squared 0.9652 
F test to compare variances 
F, DFn, Dfd 15.79, 2, 2 
P value 0.1191 
P value summary ns 
Are variances significantly different? No 
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Table 5iii:  Statistical analysis using ANOVA for LASS4 in 24h apoptosis treated Hec-1A cells 
Table Analysed Data 1 
Column A L4 Hec-1A 0h 
vs vs 
Column B L4 Hec-1A 24h 
Unpaired t test 
P value 0.0003 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 11.69, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.2233 ± 0.03283 N=3 
Difference between means 0.7767 ± 0.06642 
95% confidence interval 0.5923 to 0.9610 
R squared 0.9716 
F test to compare variances 
F, DFn, Dfd 3.093, 2, 2 
P value 0.4887 
P value summary ns 
Are variances significantly different? No 
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LASS4 colon treatments 
Table 5iv:  Statistical analysis for LASS4 in Caco-2 cells after 24h apoptosis treatment using 
ANOVA test 
Table Analysed Data 1 
Column A L4 Caco-2 oh 
vs vs 
Column B L4 Caco-2 24h 
Unpaired t test 
P value 0.0172 
P value summary * 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 3.920, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.5000 ± 0.1137 N=3 
Difference between means 0.5000 ± 0.1275 
95% confidence interval 0.1459 to 0.8541 
R squared 0.7935 
F test to compare variances 
F, DFn, Dfd 3.880, 2, 2 
P value 0.4098 
P value summary ns 
Are variances significantly different? No 
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Table 5v:  Statistical analysis for LASS4 in Caco-2 cells after 48h apoptosis treatment using 
ANOVA test 
Table Analysed Data 1 
Column A L4 Caco-2 0h 
vs vs 
Column B L4 Caco-2 48h 
Unpaired t test 
P value 0.0031 
P value summary ** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 6.361, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.3400 ± 0.08622 N=3 
Difference between means 0.6600 ± 0.1038 
95% confidence interval 0.3720 to 0.9480 
R squared 0.9100 
F test to compare variances 
F, DFn, Dfd 2.230, 2, 2 
P value 0.6192 
P value summary ns 
Are variances significantly different? No 
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Table 5vi:  Statistical analysis for LASS4 in HT-29 cells after 24h apoptosis treatment using 
ANOVA test 
Table Analysed Data 1 
Column A L4 HT-29 0h 
vs vs 
Column B L4 HT-29 24h 
Unpaired t test 
P value 0.6668 
P value summary ns 
Are means signif. different? (P <0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t = 0.4639, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.8000 ± 0.4272 N=3 
Difference between means 0.2000 ± 0.4311 
95% confidence interval -0.9967 to 1.397 
R squared 0.05106 
F test to compare variances 
F, DFn, Dfd 54.75, 2, 2 
P value 0.0359 
P value summary * 
Are variances significantly different? Yes 
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Table 5vii:  Statistical analysis for LASS4 in HT-29 cells after 48h apoptosis treatment using 
ANOVA test 
Table Analysed Data 1 
Column A L4 HT-29 0h 
vs vs 
Column B L4 HT-29 48h 
Unpaired t test 
P value 0.0059 
P value summary ** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 5.347, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.2667 ± 0.1244 N=3 
Difference between means 0.7333 ± 0.1372 
95% confidence interval 0.3526 to 1.114 
R squared 0.8773 
F test to compare variances 
F ,DFn, Dfd 4.643, 2, 2 
P value 0.3544 
P value summary ns 
Are variances significantly different? No 
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Tables for LASS5 
LASS5 endometrium 
Table 5viii:  ANOVA test for LASS5 in endometrial cells 
Table Analysed Data 1 
Column A L5 GMMe 
vs vs 
Column B L5 Hec-1A 
Unpaired t test 
P value 0.0007 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 9.589, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 43.24 ± 4.405 N=3 
Difference between means -42.24 ± 4.405 
95% confidence interval -54.47 to -30.01 
R squared 0.9583 
F test to compare variances  
F, DFn, Dfd 5821, 2, 2 
P value 0.0003 
P value summary *** 
Are variances significantly different? Yes 
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Table 5ix:  ANOVA test for LASS5 in GMMe cells after 24h apoptosis treatment 
Table Analysed Data 1 
Column A L5 GMMe 0h 
vs vs 
Column B L5 GMMe 24h 
Unpaired t test 
P value 0.0001 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 14.67, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.1433 ± 0.008819 N=3 
Difference between means 0.8567 ± 0.05840 
95% confidence interval 0.6945 to 1.019 
R squared 0.9817 
F test to compare variances 
F, DFn, Dfd 42.86, 2, 2 
P value 0.0456 
P value summary * 
Are variances significantly different? Yes 
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Table 5x:  ANOVA test for LASS5 in Hec-1A cells after 24h apoptosis treatment 
Table Analysed Data 1 
Column A L5 Hec-1A oh 
vs vs 
Column B L5 Hec-1A 24h 
Unpaired t test 
P value P <0.0001 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 15.87, df=4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.0700 ± 0.01000 N=3 
Difference between means 0.9300 ± 0.05859 
95% confidence interval 0.7673 to 1.093 
R squared 0.9844 
F test to compare variances  
F, DFn, Dfd 33.33, 2, 2 
P value 0.0583 
P value summary ns 
Are variances significantly different? No 
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LASS5 colon cells 
Table 5xi:  ANOVA test for LASS5 in colon cells  
Table Analysed Data 1 
Column A L5 Caco-2 
vs vs 
Column B L5 HT-29 
Unpaired t test  
P value 0.0050 
P value summary ** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 5.612, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 25.20 ± 4.312 N=3 
Difference between means -24.20 ± 4.312 
95% confidence interval -36.17 to -12.23 
R squared 0.8873 
F test to compare variances 
F, DFn, Dfd 5577, 2, 2 
P value 0.0004 
P value summary *** 
Are variances significantly different? Yes 
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Table xii:  ANOVA test for LASS5 in Caco-2 cells after 24h apoptosis treatment 
Table Analysed Data 1 
Column A L5 Caco-2 oh 
vs vs 
Column B L5 Caco-2 24h 
Unpaired t test 
P value 0.1839 
P value summary ns 
Are means signif. different? (P <0.05) No 
One- or two-tailed P value? Two-tailed 
t, df t = 1.604, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.6633 ± 0.2018 N=3 
Difference between means 0.3367 ± 0.2099 
95% confidence interval -0.2459 to 0.9193 
R squared 0.3915 
F test to compare variances 
F, DFn, Dfd 12.21, 2, 2 
P value 0.1514 
P value summary ns 
Are variances significantly different? No 
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Table xiii:  ANOVA test for LASS5 in Caco-2 cells after 48h apoptosis treatment 
Table Analysed Data 1 
Column A L5 Caco-2 oh 
vs vs 
Column B L5 Caco-2 48h 
Unpaired t test 
P value 0.0003 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 11.85, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.1333 ± 0.04485 N=3 
Difference between means 0.8667 ± 0.07311 
95% confidence interval 0.6637 to 1.070 
R squared 0.9723 
F test to compare variances 
F, DFn, Dfd 1.657, 2, 2 
P value 0.7526 
P value summary ns 
Are variances significantly different? No 
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Table xiv:  ANOVA test for LASS5 in HT-29 cells after 24h apoptosis treatment 
Table Analysed Data 1 
Column A L5 HT-29 oh 
vs vs 
Column B L5 HT-29 24h 
Unpaired t test 
P value P <0.0001 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 16.15, df = 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.05667 ± 0.008819 N=3 
Difference between means 0.9433 ± 0.05840 
95% confidence interval 0.7812 to 1.105 
R squared 0.9849 
F test to compare variances  
F, DFn, Dfd 42.86, 2, 2 
P value 0.0456 
P value summary * 
Are variances significantly different? Yes 
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Table xv:  ANOVA test for LASS5 in HT-29 cells after 48h apoptosis treatment 
Table Analysed Data 1 
Column A L5 HT-29 oh 
vs vs 
Column B L5 HT-29 48h 
Unpaired t test 
P value P <0.0001 
P value summary *** 
Are means signif. different? (P <0.05) Yes 
One- or two-tailed P value? Two-tailed 
t, df t = 16.92, d f= 4 
How big is the difference? 
Mean ± SEM of column A 1.000 ± 0.05774 N=3 
Mean ± SEM of column B 0.01667 ± 0.006667 N=3 
Difference between means 0.9833 ± 0.05812 
95% confidence interval 0.8220 to 1.145 
R squared 0.9862 
F test to compare variances 
F, DFn, Dfd 75.00, 2, 2 
P value 0.0263 
P value summary * 
Are variances significantly different? Yes 
 
